Pills

This is the text extract for Schedule Update - effective 1 August 2013, browse documents here.


Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 August 2013

Cumulative for May, June, July and August 2013


Contents

Summary of PHARMAC decisions effective 1 August 2013 ............................ 3 Pharmacist Prescribers – new designated prescribers ................................... 6 Risperidone out-of-stock ............................................................................... 7 Progesterone 100 mg caps – new listing ....................................................... 7 Chloramphenicol ear drops 0.5% .................................................................. 7 Oxycodone hydrochloride brand change ....................................................... 7 Hospital Medicines List .................................................................................. 7 NPPA forms downloadable ............................................................................ 8 New preservative free eye drops listings........................................................ 8 New Pharmacode for Zyban .......................................................................... 8 Coversyl – temporary higher subsidy by endorsement................................... 8 Prednisone 1 mg tablets out-of-stock ........................................................... 8 Funding for Ticagrelor ................................................................................... 9 News in brief ................................................................................................. 9 Tender News ................................................................................................ 10 Looking Forward ......................................................................................... 10 Sole Subsidised Supply products cumulative to August 2013 ..................... 11 New Listings ................................................................................................ 20 Changes to Restrictions, Chemical Names and Presentations ...................... 24 Changes to Subsidy and Manufacturer’s Price............................................. 49 Changes to General Rules............................................................................ 55 Changes to Brand Name ............................................................................. 59 Changes to Section I ................................................................................... 60 Changes to Section E .................................................................................. 61 Delisted Items ............................................................................................. 62 Items to be Delisted .................................................................................... 65 Index ........................................................................................................... 69

2


Summary of PHARMAC decisions

EFFECTIVE 1 AUGUST 2013 New listings (page 20) • Prednisone (Apo-Prednisone S29) tab 1 mg – Section 29 • Progesterone (Utrogestan) cap 100 mg – Special Authority – Retail pharmacy • Oxycodone hydrochloride (Oxycodone BNM) tab controlled-release 10 mg, 20 mg, 40 mg and 80 mg • Quetiapine (Dr Reddy’s Quetiapine) tab 100 mg – 90 tab pack size • Bupropion hydrochloride (Zyban) tab modified-release 150 mg – new Pharmacode • Macrogol 400 and propylene glycol (Systane Unit Dose) eye drops 0.4% and propylene glycol 0.3%, 0.4 ml – Special Authority- Retail pharmacy • Carbomer (Poly-Gel) ophthalmic gel 0.3%, 0.5 g – Special Authority – Retail pharmacy • Oral Feed 2 kcal/ml (Two Cal HN) liquid (vanilla) 200 ml OP – Special Authority – Retail pharmacy – Higher subsidy with Endorsement Changes to restrictions, chemical names and presentation (pages 24-27) • Insulin pump infusion set (steel cannula) – amended restriction • Insulin pump infusion set (teflon cannula, angle insertion with insertion device) – amended restriction • Insulin pump infusion set (teflon cannula, angle insertion) – amended restriction • Insulin pump infusion set (teflon cannula, straight insertion with insertion device) – amended restriction • Insulin pump infusion set (teflon cannula, straight insertion) – amended restriction • Insulin pump reservoir – amended restriction • Perindopril (Coversyl) tab 2 mg and 4 mg – Higher subsidy by Endorsement • Diltiazem (Apo-Diltiazem CD) cap long-acting 120 mg, 180 mg 240 mg – removal of brand switch fee payable • Hydrocortisone (Solu-Cortef) inj 100 mg vial – change to presentation description • Prednisone (Apo-Prednisone and Apo-Prednisone S29) tab 1 mg – reinstate STAT • Cephalexin monohydrate - amendment of chemical name to cefalexin monohydrate • Neostigmine – amendment of chemical name to neostigmine metilsulfate • Alendronate for Osteoporosis – Special Authority note amendment • Raloxifene hydrochloride (Evista) tab 60 mg – Special Authority note amendment

3


Summary of PHARMAC decisions – effective 1 August 2013 (continued) • Zoledronic acid (Aclasta) soln for infusion 5 mg in 100 ml – Special Authority note amendment • Fentanyl citrate – amendment of chemical name to fentanyl • Mianserin hydrochloride (Tolvon) tab 30 mg – removal of Special Authority • Olanzapine pamoate monohydrate (Zyprexa Relprevv) inj 210 mg, 300 mg and 405 mg – amendment of chemical name to olanzapine • Buspirone hydrochloride (Pacific Buspirone) tab 5 mg and 10 mg – removal of Special Authority • Naltrexone hydrochloride (Naltraccord) tab 50 mg – Special Authority amendment • Dacarbazine (Hospira) inj 200 mg vial – amendment of presentation description • Mesna (Uromexitan) inj 100 mg per ml, 4 ml and 10ml ampoule – amendment of presentation description • Mitomycin C (Arrow) inj 5 mg vial – amendment of presentation description • Hypromellose (Poly-Tears) – amendment of chemical name to hypromellose with dextran and amended presentation description • Adult Products High Calorie amended to High Calorie Products Decreased subsidy (pages 49-50) • Indapamide (Dapa-Tabs) tab 2.5 mg • Cefalexin monohydrate (Cephalexin ABM) cap 500 mg • Clindamycin (Clindamycin ABM) cap hydrochloride 150 mg • Itraconazole (Itrazole) cap 100 mg • Interferon beta-1-alpha (Avonex) inj 6 million iu per vial and inj 6 million prefilled syringe, (Avonex Pen) inj 6 million iu per 0.5 ml pen injector • Naltrexone hydrochloride (Naltraccord) tab 50 mg • Hypromellose with dextran (Poly-Tears) eye drops 0.3% with dextran 0.1% Increased subsidy (pages 49-50) • Warfarin sodium (Marevan) tab 1 mg, 3 mg and 5 mg • Perindopril (Coversyl) tab 2 mg and 4 mg (increase alternate subsidy) • Nifedipine (Nyefax Retard) tab long-acting 20 mg • Hydrocortisone (Solu-Cortef) inj 100 mg vial • Zidovudine [AZT] (Retrovir) cap 100 mg and oral liq 10 mg per ml • Colchicine (Colgout) tab 500 mcg • Dantrolene (Dantrium) cap 25 mg and 50 mg • Haloperidol (Serenace) tab 500 mcg, 1.5 mg and 5 mg; oral liq 2 mg per ml and inj 5 mg per ml, 1 ml

4


Summary of PHARMAC decisions – effective 1 August 2013 (continued) • Mercaptopurine (Puri-nethol) tab 50 mg • Dacarbazine (Hospira) inj 200 mg vial and (Baxter) inj 200 mg for ECP • Mesna (Uromitexan) tab 400 mg, tab 600 mg, inj 100 mg per ml, 4 ml ampoule, inj 100 mg per ml, 10 ml ampoule, and (Baxter) inj 1 mg for ECP • Mitomycin C (Arrow) inj 5 mg vial and (Baxter) inj 1 mg for ECP

5


6 Pharmaceutical Schedule - Update News

Pharmacist Prescribers – new designated prescribers

The Pharmacist Prescriber scope of practice was introduced in July 2013. PHARMAC will begin subsidy for Pharmacist Prescriber prescriptions from 1 August 2013. Pharmacist Prescribers will be able to prescribe from a wide range of medicines (approximately 1,500 items) and a limited number of controlled drugs. The lists of these pharmaceuticals can be accessed on the legislation website www.legislation. co.nz. The Pharmacy Council of New Zealand is currently receiving applications from pharmacists for registration as a Pharmacy Prescriber. Once a Pharmacy Prescriber’s registration is confirmed, the Pharmacy Council will update its register. If you receive a prescription from a Pharmacist Prescriber that you are not familiar with, please check the scope of practice on the Pharmacy Council website to ensure the pharmacist has the Pharmacist Prescriber scope of practice. www.pharmacycouncil. org.nz/register_search The Pharmacy Council is expecting no more than 14 applications for Pharmacist Prescribers in the first year. Pharmacist Prescribers will not be able to apply for Special Authority approvals. However they can prescribe a medicine where a patient already has a Special Authority approval. This applies where the Pharmaceutical Schedule rules permit a subsidy for Pharmacist Prescribers and where they are legally able to prescribe it. Pharmacist Prescribers will be able to prescribe up to three months’ supply for a Community Pharmaceutical, and up to six months’ supply for an oral contraceptive. They will also be able to prescribe up to three days’ supply for controlled drugs; this includes Class B and Class C controlled drugs.


Pharmaceutical Schedule - Update News

7

Risperidone out-of-stock

Currently the Apotex and Dr Reddy's brands of risperidone are out-of-stock. The Ridal brand, supplied by Douglas Pharmaceuticals, remains in stock and Douglas have sufficient stock to supply the market. At this time it is not known when the out-of-stock brands will be back in stock.

Progesterone 100 mg caps – new listing

Progesterone 100 mg caps (Utrogestan) will be fully funded subject to a Special Authority for the prevention of pre-term labour from 1 August 2013.

Chloramphenicol ear drops 0.5%

Pfizer NZ has advised that due to a change in manufacturing supplier, Chloromycetin ear drops (chloramphenicol 0.5% in 5 ml bottle) are no longer available, effective immediately. However, Chlorafast eye drops (chloramphenicol 0.5% in 10 ml bottle) is now funded for use in the ear. Chloromycetin ear drops will remain funded until 1 February 2014 to allow for all current stock in the supply chain to be depleted.

Oxycodone hydrochloride brand change

A new brand of oxycodone hydrochloride controlled-release tablets (Oxydone BNM) will be listed from 1 August 2013. The OxyContin brand will have a subsidy decrease from 1 October 2013 and will be delisted from 1 January 2014. A Brand Switch Fee will be payable on dispensing of Oxydone BNM from 1 January 2014 for 1 month.

Hospital Medicines List

Last month DHB hospitals started using the new Section H, known as the HML (Hospital Medicines List). There is no change for community pharmacies and they should continue to dispense in accordance with the community Pharmaceutical Schedule listings. A hospital pharmacy must dispense according to HML rules, including when dispensing to an outpatient.


8

Pharmaceutical Schedule - Update News

NPPA forms downloadable

The NPPA application forms on the PHARMAC website have been upgraded. These forms are now all in a downloadable, electronic format that applicants can complete on their computer desktops using Microsoft Word. The forms provide several new functions and they can be: stored when partially completed for completion at a later time, sent over DHB intranets to other staff for their input, and copies can be saved in the patient file. The forms can also be submitted to PHARMAC over the web along with attachments.

New preservative free eye drops listings

• Systane Unit Dose (macrogol 400 0.4% with propylene glycol 0.3%) 0.4 ml eye drops will be listed fully funded subject to Special Authority and Sole Supply from 1 August 2013. • Poly-Gel (carbomer) 0.3% ophthalmic gel, 0.5 g will be listed fully funded and subject to Special Authority and Sole Supply from 1 August 2013.

New Pharmacode for Zyban

From 1 August 2013, there is a price and subsidy reduction for bupropion hydrochloride (Zyban) modified release tablets. GSK has advised that there will be a new Pharmacode for the stock supplied at the new price. The old Pharmacode will be delisted from 1 August 2013.

Coversyl – temporary higher subsidy by endorsement

Patients receiving a higher subsidy by endorsement for the Coversyl brand of perindopril prior to 1 May 2013 will be able to access this higher subsidy from 1 August 2013. The higher subsidy by endorsement will be available for a 2 month period ending 30 September 2013.

Prednisone 1 mg tablets out-of-stock

Prednisone (Apo-Prednisone) 1 mg tablets, supplied by Apotex, is temporarily out-of-stock due to manufacturing issues. Resupply is expected in August/September 2013. In the meantime, Apotex have sourced Canadian packaged stock which will be supplied under Section 29 of the Medicines Act 1981 and will be listed fully funded from 1 August 2013. The STAT symbol will also be re-instated to prednisone 1 mg tablets. If a Pharmacist considers monthly dispensing is required, they may dispense monthly under Rule 4.2 of the Dispensing Frequency Rule.


Pharmaceutical Schedule - Update News

9

Funding of Ticagrelor

Ticagrelor (Brilinta) 90 mg tablets were listed fully funded from 1 July 2013 subject to Special Authority criteria for acute coronary syndromes. Patients who were started on ticagrelor as part of Astra Zeneca’s patient familiarisation program (Brilinta Access Program) need to continue accessing treatment through that program and not through the Pharmaceutical Schedule.

News in brief

• A new 90-tab pack size of Dr Reddy’s Quetiapine tab 100 mg will be funded from 1 August 2013. • Lucrin Depot (leuprorelin inj 3.75 mg and 11.25 mg) will be delisted from 1 February 2014. Lucrin Depot PDS (leuprorelin inj 3.75 mg, 11.25 mg and 30 mg prefilled syringe) will remain fully funded. • The Special Authorities will be removed from buspirone hydrochloride and mianserin hydrochloride from 1 August 2013. • The Special Authority approval periods for naltrexone hydrochloride will be increased from 3 months to 6 months from 1 August 2013 and there will no longer be any restriction on how many approvals can be granted within a 12-month period. • The subsidy for Dantrium (dantrolene cap 25 mg and 50 mg) will be increased from 1 August 2013 so that it will become fully funded. • The Batrafen brand of ciclopirox olamine nail soln 5% 3 g OP is to be delisted from 1 October 2013. • From 1 August 2013 the manufacturers price of Diprosone and Diprosone OV has reduced making it fully funded.


Tender News

Sole Subsidised Supply changes – effective 1 September 2013

Chemical Name Amiodarone hydrochloride Presentation; Pack size Inj 50 mg per ml, 3 ml ampoule; 6 inj Sole Subsidised Supply brand (and supplier) Cordarone-X (Sanofi)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for future implementation 1 September 2013 • Boceprevir (Victrelis) cap 200 mg – new listing – Special Authority • Desmopressin acetate (Minirin) tab 100 mcg and 200 mcg – new listing – Special Authority • Imiglucerase – widen Special Authority criteria • Mesalazine (Pentasa) modified release granules 1 g, 120 g OP – new listing – Special Authority • Mycophenolate mofetil (Cellcept) cap 250 mg and 500 mg – price and subsidy decrease • Risedronate (Risedronate Sandoz) tab 35 mg – new listing • Venlafaxine (Arrow-Venlafaxine XR brand only) tab 37.5 mg, 75 mg, 150 mg and 225 mg – price and subsidy decrease and removal of Special Authority

10


Sole Subsidised Supply Products – cumulative to August 2013

Generic Name

Abacavir sulphate Acarbose Acetazolamide Acetylcysteine Allopurinol Amantadine hydrochloride Aminophylline Amisulpride Amitriptyline Amlodipine Amoxycillin Amoxycillin clavulanate

Presentation

Oral liq 20 mg per ml Tab 300 mg Tab 50 mg and 100 mg Tab 250 mg Inj 200 mg per ml, 10 ml Tab 100 mg & 300 mg Cap 100 mg Inj 25 mg per ml, 10 ml Oral liq 100 mg per ml Tab 100 mg, 200 mg & 400 mg Tab 10 mg Tab 25 mg & 50 mg Tab 2.5 mg Tab 5 mg & 10 mg Inj 250 mg, 500 mg & 1 g Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab 500 mg with potassium clavulanate 125 mg Crm Tab 50 mg & 100 mg Tab 10 mg, 20 mg, 40 mg & 80 mg Inj 600 mcg, 1 ml Tab 500 mg Tab 10 mg Tab 2.5 mg & 5 mg Inj 1.2 mega u per 2.3 ml Inj 600 mg Eye drops 0.5% Eye drops 0.25% Tab 200 mg Tab long-acting 400 mg Tab 50 mg

Brand Name Expiry Date*

Ziagen Ziagen Accarb Diamox Martindale Acetylcysteine Apo-Allopurinol Symmetrel DBL Aminophylline Solian Arrow-Amitriptyline Amitrip Apo-Amlodipine Apo-Amlodipine Ibiamox Augmentin Augmentin Curam Duo AFT Mylan Atenolol Zarator AstraZeneca Apo-Azithromycin Pacifen ArrowBendrofluazide Bicillin LA Sandoz Betoptic Betoptic S Bezalip Bezalip Retard Bicalaccord 2014 2014 2015 2015 2015 2015 2016 2014 2015 2014 2014 2015 2014 2014 2015 2014 2015 2014 2014 2014 2016 2014 2014 2014 2015

Aqueous cream Atenolol Atorvastatin Atropine sulphate Azithromycin Baclofen Bendrofluazide Benzathine benzylpenicillin Benzylpenicillin sodium (Penicillin G) Betaxolol hydrochloride Bezafibrate Bicalutamide

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

11


Sole Subsidised Supply Products – cumulative to August 2013

Generic Name

Blood glucose diagnostic test meter Blood glucose diagnostic test strip Brimonidine tartrate Cabergoline Calamine Calcitonin Calcium carbonate Calcium folinate Candesartan Carbomer Cefazolin sodium Cefuroxime sodium Cetirizine hydrochloride Chloramphenicol Chlorhexidine gluconate

Presentation

Meter with 50 lancets, a lancing device and 10 diagnostic test strips Blood glucose test strips Eye drops 0.2% Tab 0.5 mg Lotn, BP Inj 100 iu per ml, 1 ml Tab 1.25 g (500 mg elemental) Tab eff 1.75 g (1 g elemental) Tab 15 mg Tab 4 mg, 8 mg, 16 mg & 32 mg Ophthalmic gel 0.3%, 0.5 g Inj 500 mg & 1 g Inj 750 mg Oral liq 1 mg per ml Tab 10 mg Eye oint 1% Eye drops 0.5% Mouthwash 0.2% Handrub 1% with ethanol 70% Soln 4% Nail-soln 8% Tab 250 mg, 500 mg & 750 mg Tab 20 mg Tab 500 mg Tab 250 mg Tab 10 mg & 25 mg Tab 150 mcg Inj 150 mcg per ml, 1 ml Crm 1% Tab 15 mg, 30 mg & 60 mg Crm 10% Tab 50 mg Oral liq 100 mg per ml Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs

Brand Name Expiry Date*

CareSens N CareSens N POP CareSens II CareSens CareSens N Arrow-Brimonidine Dostinex PSM Miacalcic Arrow-Calcium Calsource DBL Leucovorin Calcium Candestar Poly-Gel AFT Multichem Cetirizine - AFT Zetop Chlorsig Chlorafast healthE healthE Orion Apo-Ciclopirox Cipflox Arrow-Citalopram Apo-Clarithromycin Apo-Clarithromycin Apo-Clomipramine Catapres Clomazol PSM Itch-Soothe Nausicalm Neoral Siterone Ginet 84 2015

2015 2014 2015 2015 2014 2014 2014 2015 2016 2014 2014 2014 2015 2015 2014 2015 2014 2014 2014 2015 2015 2014 2016 2015 2015 2015 2015 2014

Ciclopirox olamine Ciprofloxacin Citalopram hydrobromide Clarithromycin Clomipramine hydrochloride Clonidine hydrochloride Clotrimazole Codeine phosphate Crotamiton Cyclizine hydrochloride Cyclosporin Cyproterone acetate Cyproterone acetate with ethinyloestradiol

12

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to August 2013

Generic Name

Desmopressin Dexamethasone

Presentation

Nasal spray 10 mcg per dose Tab 1 mg & 4 mg Eye oint 0.1%

Brand Name Expiry Date*

Desmopressin-PH&T Douglas Maxidex Maxitrol Maxitrol 2014 2015 2014 2014

Dexamethasone with neomycin Eye oint 0.1% with neomycin sulphate and polymyxin b sulphate 0.35% and polymyxin B sulphate 6,000 u per g Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml Dexamphetamine sulphate Dextrose Diclofenac sodium Tab 5 mg Inj 50%, 10 ml Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Inj 25 mg per ml, 3 ml Eye drops 1 mg per ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab 30 mg & 60 mg Tab long-acting 150 mg Cap 50 mg Cap 120 mg Tab 10 mg Tab 2 mg & 4 mg Tab 100 mg Oint BP Tab 5 mg, 10 mg & 20 mg Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Inj 500 mcg per ml, 1 ml Tab 200 mg Tab 10 mcg Tab 20 mcg with levonorgestrel 100 mcg & 7 inert tab Tab 30 mcg with levonorgestrel 150 mcg & 7 inert tab Tab 25 mg Tab long-acting 5 mg & 10 mg Tab long-acting 2.5 mg

PSM Biomed Apo-Diclo Diclax SR Voltaren Voltaren Ophtha Voltaren Apo-Diltiazem CD Dilzem Pytazen SR Laxofast 50 Laxofast 120 Prokinex Apo-Doxazosin Doxine AFT m-Enalapril Clexane Entapone DBL Ergometrine Arrow-Etidronate NZ Medical and Scientific Ava 20 ED Ava 30 ED Aromasin Plendil ER Plendil ER

2015 2014 2015 2014

Diltiazem hydrochloride

2015

Dipyridamole Docusate sodium Domperidone Doxazosin mesylate Doxycycline hydrochloride Emulsifying ointment Enalapril Enoxaparin sodium Entacapone Ergometrine maleate Etidronate disodium Ethinyloestradiol Ethinyloestradiol with levonorgestrel

2014 2014 2015 2014 2014 2014 2015 2015 2015 2014 2015 2015 2014

Exemestane Felodopine

2014 2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

13


Sole Subsidised Supply Products – cumulative to August 2013

Generic Name

Fentanyl Filgrastim Finasteride Flucloxacillin sodium

Presentation

Inj 50 mcg per ml, 2 ml & 10 ml Inj 300 mcg per 0.5 ml Inj 480 mcg per 0.5 ml Tab 5 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap 250 mg & 500 mg Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Eye drops 0.1% Crm 5% Metered aqueous nasal spray, 50 mcg per dose Tab 500 mg Tab 40 mg Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Suppos 3.6 g Aerosol spray 400 mcg per dose TDDS 5 mg & 10 mg Tab 600 mcg Tab 5 mg & 20 mg Crm 1% Powder Rectal foam 10%, CFC-Free (14 applications) Lipocream 0.1% Milky emul 0.1% Oint 0.1% Scalp lotn 0.1% Lotn 1% with wool fat hydrous 3% and mineral oil Inj 1 mg per ml, 1 ml Tab 200 mg Inj 20 mg, 1 ml Tab 10 mg Tab 200 mg Tab long-acting 800 mg Crm 5%

Brand Name Expiry Date*

Boucher and Muir Zarzio Zarzio Rex Medical AFT Staphlex Flucloxin Ozole Flucon Efudix Flixonase Hayfever & Allergy Urex Forte Diurin 40 Pfizer Apo-Gliclazide Minidiab PSM Glytrin Nitroderm TTS Lycinate Douglas Pharmacy Health ABM Colifoam Locoid Lipocream Locoid Crelo Locoid Locoid DP Lotn HC ABM Hydroxocobalamin Plaquenil Buscopan Gastrosoothe Arrowcare Brufen SR Aldara 2015

31/12/15

2014 2015 2014 2014 2015 2015 2015 2015 2015 2014 2015 2015 2014

Fluconazole Fluorometholone Fluorouracil sodium Fluticasone propionate Furosemide Gentamicin sulphate Gliclazide Glipizide Glycerol Glyceryl trinitrate

Hydrocortisone

2015 2014 2015 2015

Hydrocortisone acetate Hydrocortisone butyrate

Hydrocortisone with wool fat and mineral oil Hydroxocobalamin Hydroxychloroquine sulphate Hyoscine N-butylbromide Ibuprofen Imiquimod

2014 2015 2015 2014 2014 2014

14

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to August 2013

Generic Name

Iron polymaltose Isoniazid Isosorbide mononitrate Isotretinoin Ketoconazole Lamivudine Lansoprazole Latanoprost Letrozole Levonorgestrel Lignocaine hydrochloride Lisinopril Lithium carbonate Lodoxamide trometamol Losartan Losartan with hydrochlorothiazide Macrogol 400 and propylene glycol Mask for spacer device Mebendazole Mebeverine hydrochloride Megestrol acetate Methylprednisolone Methylprednisolone acetate Methylprednisolone acetate with lignocaine Mesalazine Metformin hydrochloride Methadone hydrochloride

Presentation

Inj 50 mg per ml, 2 ml Tab 100 mg Tab 20 mg Tab long-acting 40 mg Cap 10 mg & 20 mg Shampoo 2% Tab 100 mg Cap 15 mg & 30 mg Eye drops 50 mcg per ml Tab 2.5 mg Subdermal implant (2 x 75 mg rods) Viscous soln 2% Tab 5 mg, 10 mg & 20 mg Tab 250 mg & 400 mg Cap 250 mg Eye drops 0.1% Tab 12.5 mg, 25 mg, 50 mg & 100 mg Tab 50 mg with hydrochlorothiazide 12.5 mg Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml Size 2 Tab 100 mg Tab 135 mg Tab 160 mg Tab 4 mg & 100 mg Inj 40 mg per ml Inj 40 mg per ml with lignocaine 1 ml Enema 1 g per 100 ml Suppos 500 mg Tab immediate-release 500 mg & 850 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml

Brand Name Expiry Date*

Ferrum H PSM Ismo 20 Corangin Oratane Sebizole Zetlam Solox Hysite Letraccord Jadelle Xylocaine Viscous Arrow-Lisinopril Lithicarb FC Douglas Lomide Lostaar Arrow-Losartan & Hydroclorothiazide Systane Unit Dose EZ-fit Paediatric Mask De-Worm Colofac Apo-Megestrol Medrol Depo-Medrol Depo-Medrol with Lidocaine Pentasa Asacol Apotex Biodone Biodone Forte Biodone Extra Forte 2014 2015 2014 2015 2014 2014 2015 2015 2015 31/12/13 2014 2015 2015 2014 2014 2014 2014 2016 2015 2014 2014 2015 2015 2015 2015 2015 2014 2015 2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

15


Sole Subsidised Supply Products – cumulative to August 2013

Generic Name

Methylprednisolone sodium succinate Metoclopramide hydrochloride Metoprolol succinate Metoprolol tartrate

Presentation

Inj 40 mg per ml, 1 ml; 62.5 mg per ml, 2 ml; 500 mg & 1 g Inj 5 mg per ml, 2 ml Tab 10 mg Tab long-acting 23.75 mg, 47.5 mg, 95 mg & 190 mg Inj 1 mg per ml, 5 ml Tab 50 mg & 100 mg Tab long-acting 200 mg Oral gel 20 mg per g Crm 2% Tab 30 mg & 45 mg Tab 150 mg & 300 mg Crm 0.1% Oint 0.1% Oral liq 1 mg per ml, 2 mg per ml, 5 mg per ml & 10 mg per ml Inj 5 mg per ml, 1 ml Inj 10 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Inj 30 mg per ml, 1 ml

Brand Name Expiry Date*

Solu-Medrol Pfizer Metamide Metoprolol-AFT CR Lopresor Lopresor Slow-Lopresor Decozol Multichem Avanza Apo-Moclobemide m-Mometasone RA-Morph DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate DBL Morphine Sulphate Naphcon Forte Apo-Nadolol Noflam 250 Noflam 500 AstraZeneca Nevirapine Alphapharm Habitrol Habitrol Habitrol Apo-Nicotinic Acid Noriday 28 Primolut N Arrow-Norfloxacin Norpress Nilstat 2014 2015 2014 2014 2016 2014 2015 2014 2015 2015

Miconazole Miconazole nitrate Mirtazapine Moclobemide Mometasone furoate Morphine hydrochloride Morphine sulphate

2015 2014 2015 2015 2015 2015 2014

Naphazoline hydrochloride Nadolol Naproxen Neostigmine Nevirapine Nicotine

Eye drops 0.1% Tab 40 mg & 80 mg Tab 250 mg Tab 500 mg Inj 2.5 mg per ml, 1 ml Tab 200 mg Gum 2 mg & 4 mg (classic, fruit, mint) Lozenge 1 mg & 2 mg Patch 7 mg, 14 mg & 21 mg Tab 50 mg & 500 mg Tab 350 mcg Tab 5 mg Tab 400 mg Tab 10 mg & 25 mg Oral liq 100,000 u per ml

2014 2015 2015 2014 2015 2014

Nicotinic acid Norethisterone Norfloxacin Nortriptyline hydrochloride Nystatin

16

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to August 2013

Generic Name

Octreotide (somatostatin analogue) Oil in water emulsion Omeprazole

Presentation

Inj 50 mcg per ml, 1 ml Inj 100 mcg per ml, 1 ml Inj 500 mcg per ml, 1 ml Crm Cap 10 mg, 20 mg & 40 mg Powder Inj 40 mg Tab 10 mg & 15 mg Oral liq 5 mg per ml Tab 5 mg Inj 50 mg per ml, 1 ml Inj 10 mg per ml, 1 ml & 2 ml Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Inj 3 mg per ml, 10 ml; 6 mg per ml, 10 ml & 9 mg per ml, 10 ml Inj 40 mg Suppos 500 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab paracetamol 500 mg with codeine phosphate 8 mg Low range & normal range Tab 0.25 mg & 1 mg Crm 5% Lotn 5% Tab 50 mg & 100 mg Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml

Brand Name Expiry Date*

Octreotide Max Rx 2014

healthE Fatty Cream Omezol Relief Midwest Dr Reddy’s Omeprazole Ox-Pam Apo-Oxybutynin OxyNorm Oxycodone Orion Syntometrine Pamidronate BNM Pantocid IV Paracare Parafast Ethics Paracetamol Paracare Double Strength Paracetamol + Codeine (Relieve) Breath-Alert Permax Lyderm A-Scabies PSM DBL Pethidine Hydrochloride DBL Pethidine Hydrochloride PSM Pizaccord Sandomigran Coloxyl Span-K Cholvastin Cilicaine Allersoothe Allersoothe

2015 2014

Oxazepam Oxybutynin Oxycodone hydrochloride Oxytocin Pamidronate disodium Pantoprazole Paracetamol

2014 2016 2015 2015 2014 2014 2015 2014

Paracetamol with codeine Peak flow meter Pergolide Permethrin Pethidine hydrochloride

2014 2015 2014 2014 2015 2014

Phenobarbitone Pioglitazone Pizotifen Poloxamer Potassium chloride Pravastatin Procaine penicillin Promethazine hydrochloride

Tab 15 mg & 30 mg Tab 15 mg, 30 mg & 45 mg Tab 500 mcg Oral drops 10% Tab long-acting 600 mg Tab 20 mg & 40 mg Inj 1.5 mega u Oral liq 5 mg per 5 ml Tab 10 mg & 25 mg

2015 2015 2015 2014 2015 2014 2014 2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

17


Sole Subsidised Supply Products – cumulative to August 2013

Generic Name

Pyridostigmine bromide Pyridoxine hydrochloride Quinapril Quinapril with hydrochlorothiazide

Presentation

Tab 60 mg Tab 25 mg Tab 50 mg Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Oral liq 150 mg per 10 ml Tab 150 mg & 300 mg Tab 100 mg Tab orodispersible 10 mg Tab 150 mg & 300 mg Nebuliser soln, 1 mg per ml & 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml Tab 25 mg, 50 mg & 100 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Eye drops 1 mg per ml, 10 ml OP 800 ml 230 ml (single patient) Tab 20 mg Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium, 500 ml & 1,000 ml Tab 10 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Cap 40 mg Inj 250 mcg Inj 1 mg per ml, 1 ml Eye drops 0.25% & 0.5% Eye drops 0.3% Eye oint 0.3% Inj 40 mg per ml, 2 ml

Brand Name Expiry Date*

Mestinon PyridoxADE Apo-Pyridoxine Arrow-Quinapril Accuretic 10 Accuretic 20 Peptisoothe Arrow-Ranitidine Norvir Rizamelt ArrowRoxithromycin Asthalin Duolin 2014 2015 2014 2015 2015 2015 2014 2014 2015 2015

Ranitidine hydrochloride Ritonavir Rizatriptan Roxithromycin Salbutamol Salbutamol with ipratropium bromide Sildenafil Simvastatin

Silagra Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg Hylo-Fresh Volumatic Space Chamber Plus Genox Pinetarsol

2014 2014

Sodium hyaluronate Spacer device Tamoxifen citrate Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Terbinafine Testosterone cypionate Testosterone undecanoate Tetracosactrin Timolol maleate Tobramycin

2016 2015 2014 2014

Normison Dr Reddy’s Terbinafine Depo-Testosterone Andriol Testocaps Synacthen Synacthen Depot Arrow-Timolol Tobrex Tobrex DBL Tobramycin

2014 2014 2014 2015 2014 2014 2014

18

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.


Sole Subsidised Supply Products – cumulative to August 2013

Generic Name

Tolcapone Tramadol hydrochloride Triamcinolone acetonide

Presentation

Tab 100 mg Cap 50 mg Inj 10 mg per ml, 1 ml Inj 40 mg per ml, 1 ml Crm 0.02% Oint 0.02% 0.1% in Dental Paste USP Eye drops 0.5% & 1% Cap 250 mg Inj 500 mg Tab 40 mg & 80 mg Tab 300 mg with lamivudine 150 mg Oint BP Caps 137.4 mg (50 mg elemental)

Brand Name Expiry Date*

Tasmar Arrow-Tramadol Kenacort-A Kenacort-A40 Aristocort Aristocort Oracort Mydriacyl Ursosan Mylan Isoptin Alphapharm Multichem Zincaps 2014 2014 2014

Tropicamide Ursodeoxycholic acid Vancomycin hydrochloride Verapamil hydrochloride Zidovudine [AZT] with lamivudine Zinc and castor oil Zinc sulphate August changes are in bold type

2014 2014 2014 2014 2014 2014 2014

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

19


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 August 2013

82 PREDNISONE ❋ Tab 1 mg .................................................................................. 2.13 100 ✔ Apo-Prednisone S29

S29

84

PROGESTERONE – Special Authority see SA1392 – Retail pharmacy Cap 100 mg ............................................................................ 16.50

30

✔ Utrogestan

➽ SA1392 Special Authority for Subsidy Initial application from an obstetrician or gynaecologist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1. For the prevention of pre-term labour*; and 2. Either 2.1. The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks) or 2.2. The patient has a history of pre-term birth at less than 28 weeks. Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 4.6). 122 OXYCODONE HYDROCHLORIDE a) Only on a controlled drug form b) See prescribing guideline c) No patient co-payment payable d) Safety medicine; prescriber may determine dispensing frequency Tab controlled-release 10 mg .................................................... 6.75 Tab controlled-release 20 mg ................................................. 11.50 Tab controlled-release 40 mg ................................................. 18.50 Tab controlled-release 80 mg .................................................. 34.00

20 20 20 20

✔ Oxydone BNM ✔ Oxydone BNM ✔ Oxydone BNM ✔ Oxydone BNM ✔ Dr Reddy’s Quetiapine ✔ Zyban

134

QUETIAPINE – Safety medicine; prescriber may determine dispensing frequency Tab 100 mg ............................................................................ 21.00 90 BUPROPION HYDROCHLORIDE Tab modified-release 150 mg .................................................... 4.97 Note – This Zyban has a new price and Pharmacode (2439743)

145

30

185 185 208

MACROGOL 400 AND PROPYLENE GLYCOL – Special Authority see SA1388 – Retail pharmacy Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml .................... 4.30 24 ✔ Systane Unit Dose CARBOMER – Special Authority see SA1388 – Retail pharmacy Ophthalmic gel 0.3%, 0.5 g........................................................ 8.25 30 ✔ Poly-Gel

ORAL FEED 2 KCAL/ML – Special Authority see SA1195 – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly. Liquid (vanilla) – Higher subsidy of $1.90 per 200 ml with Endorsement ......................................................................... 0.96 200 ml OP (1.90) Two Cal HN

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

20

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 July 2013

41 ASCORBIC ACID a) No more than 100 mg per dose b Only on a prescription ❋ Tab 100 mg ........................................................................... 13.80 VITAMIN B COMPLEX ❋ Tab, strong, BPC ....................................................................... 4.70 VITAMINS ❋ Tab (BPC cap strength) ............................................................ 8.00 TICAGRELOR – Special Authority see SA1382 – Retail pharmacy ❋ Tab 90 mg .............................................................................. 90.00

41 42 45

500 500 1,000 56

✔ Cvite ✔ Bplex ✔ Mvite ✔ Brilinta

➽ SA1382 Special Authority for Subsidy Initial application (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned. Renewal (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned. 48 PEGFILGRASTIM – Special Authority see SA1384 – Retail pharmacy Inj 6 mg per 0.6 ml syringe ................................................. 1,080.00 1 ✔ Neulastim

➽ SA1384 Special Authority for Subsidy Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk ≥ 20%*). *Febrile neutropenia risk ≥ 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines. 58 69 AMILORIDE HYDROCHLORIDE ❋ Tab 5 mg ................................................................................ 17.50 CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10% ....................................................... 4.50 100 500 g OP ✔ Apo-Amiloride ✔ Pharmacy Health Sorbolene with Glycerin ✔ Lidocaine-Claris ✔ Lidocaine-Claris

119

LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO .............. 8.75 Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO .............. 2.40

25 1

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

21


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 July 2013 (continued)

140 PHENOBARBITONE SODIUM – Special Authority see SA1386 – Retail pharmacy Inj 200 mg per ml, 1 ml ampoule ............................................. 46.20 10 ✔ Martindale S29

➽ SA1386 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 For the treatment of terminal agitation that is unresponsive to other agents; and 2 The applicant is part of a multidisciplinary team working in palliative care. 166 185 ADALIMUMAB – Special Authority see SA1371 – Retail pharmacy Inj 20 mg per 0.4 ml prefilled syringe .................................. 1,799.92 2 ✔ Humira ✔ Hylo-Fresh

SODIUM HYALURONATE – Special Authority see SA1388 – Retail pharmacy Eye drops 1 mg per ml ............................................................ 22.00 10 ml OP

Note: Hylo-Fresh has a 6 month expiry after opening. The Pharmacy Handbook restriction allowing one bottle per month is not relevant and therefore only the prescribed dosage to the nearest OP may be claimed. 185 PRESERVATIVE FREE OCULAR LUBRICANTS ➽ SA1388 – Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 12 months for patients meeting the following criteria: Both: 1 Confirmed diagnosis by slit lamp of severe secretory dry eye; and 2 Either: 2.1 Patient is using eye drops more than four times daily on a regular basis; or 2.2 Patient has had a confirmed allergic reaction to preservative in eye drop. Renewal from any relevant practitioner. Approvals valid for 24 months where the patient continues to require lubricating eye drops and has benefited from treatment. 185 186 198 202 RETINOL PALMITATE Eye oint 138 mcg per g ............................................................. 3.80 PHARMACY SERVICES – May only be claimed once per patient. ❋ Brand switch fee ....................................................................... 4.33 The Pharmacode for BSF Arrow-Quinapril is 2441497. 5 g OP 1 fee ✔ VitA-POS ✔ BSF Arrow-Quinapril

FAT SUPPLEMENT – Special Authority see SA1374 – Hospital pharmacy [HP3] Oil, 250 ml ............................................................................ 114.92 4 OP

✔ Liquigen

RENAL ORAL FEED 2 KCAL/ML – Special Authority see SA1101 – Hospital pharmacy [HP3] Liquid (apricot), 125 ml ........................................................... 11.52 4 OP ✔ Renilon 7.5 Liquid (caramel), 125 ml ......................................................... 11.52 4 OP ✔ Renilon 7.5

Effective 1 June 2013

39 MACROGOL 3350 – Special Authority see SA0891 – Retail pharmacy Powder 13.125 g, sachets - Maximum of 60 sach per prescription ......................................................................... 18.14

30

✔ Movicol

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

22

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 June 2013 (continued)

62 BOSENTAN – Special Authority see SA0967 – Retail pharmacy Tab 62.5 mg ..................................................................... 2,000.00 Tab 125 mg ...................................................................... 2,000.00 60 60 ✔ pms-Bosentan ✔ pms-Bosentan

211 213

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 – Hospital pharmacy [HP3] Powder (unflavoured), 29 g .................................................. 330.12 30 ✔ PKU Anamix Junior HIGH FAT LOW CARBOHYDRATE FORMULA – Special Authority see SA1197 – Retail pharmacy Powder (unflavoured) .............................................................. 35.50 300 g OP ✔ KetoCal 4:1

New Listings - effective 6 May 2013

72 MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2%......................................................................... 11.95

90 g OP

✔ Para Plus

Effective 1 May 2013

52 57 58 61 119 PERINDOPRIL ❋ Tab 2 mg ................................................................................. 3.75 ❋ Tab 4 mg ................................................................................. 4.80 CLONIDINE HYDROCHLORIDE ❋ Tab 25 mcg............................................................................. 15.09 METOLAZONE – Special Authority see SA1323 – Retail pharmacy Tab 5 mg ............................................................................. CBS 30 30 112 50 ✔ Apo-Perindopril ✔ Apo-Perindopril ✔ Clonidine BNM ✔ Zaroxolyn S29 ✔ Onelink S29 ✔ Lidocaine-Claris ✔ Lidocaine-Claris ✔ BSF Apo-Diltiazem CD

HYDRALAZINE HYDROCHLORIDE – Special Authority see SA1321 – Retail pharmacy ❋ Tab 25 mg ........................................................................... CBS 56 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Inj 2%, 5 ml – Up to 5 inj available on a PSO .............................. 6.90 Inj 2%, 20 ml – Up to 5 inj available on a PSO ............................ 2.40 PHARMACY SERVICES – May only be claimed once per patient Brand switch fee ....................................................................... 4.33 The Pharmacode for BSF Apo-Diltiazem CD is 2437775 25 1 1 fee

186

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

23


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions, Chemical Names and Presentations

Effective 1 August 2013

33 INSULIN PUMP INFUSION SET (STEEL CANNULA) – Special Authority SA1240 – Retail pharmacy a) Maximum of 3 dev per prescription b) Only on a prescription c) Maximum of 1 prescription per 90 days. dc) Maximum of 13 Note: One additional pack of infusion sets will be funded per year (Maximum of 13 pack per annum). INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE INSERTION WITH INSERTION DEVICE) – Special Authority SA1240 – Retail pharmacy a) Maximum of 3 dev per prescription b) Only on a prescription c) Maximum of 1 prescription per 90 days. dc) Maximum of 13 Note: One additional pack of infusion sets will be funded per year (Maximum of 13 pack per annum). INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE INSERTION) – Special Authority SA1240 – Retail pharmacy a) Maximum of 3 dev per prescription b) Only on a prescription c) Maximum of 1 prescription per 90 days. dc) Maximum of 13 Note: One additional pack of infusion sets will be funded per year (Maximum of 13 pack per annum). INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION WITH INSERTION DEVICE) – Special Authority SA1240 – Retail pharmacy a) Maximum of 3 dev per prescription b) Only on a prescription dc) Maximum of 13 Note: One additional pack of infusion sets will be funded per year (Maximum of 13 pack per annum). d) Maximum of 1 prescription per 90 days. INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION) – Special Authority SA1240 – Retail pharmacy a) Maximum of 3 dev per prescription b) Only on a prescription dc) Maximum of 13 Note: One additional pack of infusion sets will be funded per year (Maximum of 13 pack per annum). d) Maximum of 1 prescription per 90 days. INSULIN PUMP RESERVOIR – Special Authority SA1240 – Retail pharmacy a) Maximum of 3 dev per prescription b) Only on a prescription c) Maximum of 1 prescription per 90 days. dc) Maximum of 13 Note: One additional packs of reservoir sets will be funded per year (Maximum of 13 pack per annum).

34

35

36

37

37

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

24

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 August 2013 (continued)

52 PERINDOPRIL From 1 August 2013 to 30 September 2013 the Coversyl brand of perindopril will be funded by Endorsement to the level of the ex-manufacturer price listed in the Schedule for patients who were previously accessing the higher subsidy by endorsement for perindopril prior to 1 May 2013. ❋ Tab 2 mg – Higher subsidy of $18.50 per 30 tab with Endorsement ........................................................................ 3.75 30 (18.50) Coversyl ❋ Tab 4 mg – Higher subsidy of $25.00 per 30 tab with Endorsement ........................................................................ 4.80 30 (25.00) Coversyl DILTIAZEM HYDROCHLORIDE ❋ Cap long-acting 120 mg – brand switch fee payable ................ 31.83 ❋ Cap long-acting 180 mg – brand switch fee payable ................ 47.67 ❋ Cap long-acting 240 mg – brand switch fee payable ................ 63.58 HYDROCORTISONE (change to presentation description) ❋ Inj 50 mg per ml, 2 ml Inj 100 mg vial...................................... 4.99 PREDNISONE (addition of STAT) ❋ Tab 1 mg .................................................................................. 2.13 500 500 500 1 100 ✔ Apo-Diltiazem CD ✔ Apo-Diltiazem CD ✔ Apo-Diltiazem CD ✔ Solu-Cortef ✔ Apo-Prednisone S29

S29

57 81 82 89

❋ Tab 1 mg ................................................................................ 10.68 500 Note: the removal of the stat symbol will be temporary due to a potential out of stock CEPHALEXIN CEFALEXIN MONOHYDRATE Cap 500 mg .............................................................................. 5.70 Grans for oral liq 125 mg per 5 ml ............................................. 8.50 Grans for oral liq 250 mg per 5 ml .......................................... 11.50 NEOSTIGMINE METILSULFATE Inj 2.5 mg per ml, 1 ml ampoule ............................................ 140.00 ALENDRONATE FOR OSTEOPOROSIS (amendment to Special Authority Note) 20 100 ml 100 ml 50

✔ Apo-Prednisone

✔ Cephalexin ABM ✔ Cefalexin Sandoz ✔ Cefalexin Sandoz ✔ AstraZeneca

109 111

➽ SA1039 Special Authority for Subsidy b) Evidence used by the National Institute for Health and Clinical Excellence (NICE) guidance indicates suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates 113 RALOXIFENE HYDROCHLORIDE – Special Authority see SA1138 – Retail pharmacy (amendment to Special Authority Note) ❋ Tab 60 mg .............................................................................. 53.76 28

✔ Evista

➽ SA1138 Special Authority for Subsidy b) Evidence used by the UK National Institute for Health and Clinical Excellence (NICE) in developing its guidance indicates suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

25


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 August 2013 (continued)

114 ZOLEDRONIC ACID – Special Authority see SA1187 – Retail pharmacy (amendment to Special Authority Note) Soln for infusion 5 mg in 100 ml ....................................... 600.00

100 ml

✔ Aclasta

➽ SA1187 Special Authority for Subsidy b) Evidence used by the National Institute for Health and Clinical Excellence (NICE) guidance indicates suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates. 121 FENTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Inj 50 mcg per ml, 2 ml ............................................................. 4.50 Inj 50 mcg per ml, 10 ml ........................................................ 11.77

10 10

✔ Boucher and Muir ✔ Boucher and Muir

123

MIANSERIN HYDROCHLORIDE – Special Authority see SA1048 – Retail pharmacy (removal of Special Authority) Tab 30 mg .............................................................................. 24.86 30 ✔ Tolvon ➽ SA1048 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Both: 1.1 Depression; and 1.2 Either: 1.2.1 Co-existent bladder neck obstruction; or 1.2.2 Cardiovascular disease; or 2 Both: 2.1 The patient has a severe major depressive episode; and 2.2 Either: 2.2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or 2.2.2 Both: 2.2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and 2.2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

135

OLANZAPINE PAMOATE MONOHYDRATE – Special Authority see SA1146 – Retail pharmacy (amendment of chemical name) Safety medicine; prescriber may determine dispensing frequency Inj 210 mg ............................................................................ 280.00 1 ✔ Zyprexa Relprevv Inj 300 mg ............................................................................ 460.00 1 ✔ Zyprexa Relprevv Inj 405 mg ........................................................................... 560.00 1 ✔ Zyprexa Relprevv

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

26

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 August 2013 (continued)

137 BUSPIRONE HYDROCHLORIDE – Special Authority see SA0863 – Retail pharmacy (removal of Special Authority) Tab 5 mg ............................................................................... 28.00 100 ✔ Pacific Buspirone Tab 10 mg ............................................................................. 17.00 100 ✔ Pacific Buspirone ➽ SA0863 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 For use only as an anxiolytic; and 2 Other agents are contraindicated or have failed. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. 145 NALTREXONE HYDROCHLORIDE – Special Authority see SA13970909 – Retail pharmacy (amendment to Special Authority) Tab 50 mg ............................................................................. 76.00 30 ✔ Naltraccord ➽ SA13970909 Special Authority for Subsidy Special Authority for Subsidy Initial application from any medical practitioner. Approvals valid for 3 6 months for applications meeting the following criteria: Both: 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard. Renewal from any medical practitioner. Approvals valid for 3 6 months for applications meeting the following criteria: Both: 1 Compliance with the medication (prescriber determined); and 2 Any of the following: 2.1 Patient is still unstable and requires further treatment; or 2.2 Patient achieved significant improvement but requires further treatment; or 2.3 Patient is well controlled but requires maintenance therapy. The patient must not have had more than 1 prior approval in the last 12 months. 151 152 DACARBAZINE – PCT only – Specialist (change to presentation description) Inj 200 mg vial ....................................................................... 51.84 MESNA – PCT only – Specialist (change to presentation description) Inj 100 mg per ml, 4 ml ampoule........................................... 148.05 Inj 100 mg per ml, 10 ml ampoule......................................... 339.90 MITOMYCIN C – PCT only – Specialist (change to presentation description) Inj 5 mg vial ........................................................................... 79.75 HYPROMELLOSE WITH DEXTRAN (change to presentation description) ❋ Eye drops 0.3% with dextran 0.1% ........................................... 2.30 ADULT PRODUCTS HIGH CALORIE HIGH CALORIE PRODUCTS ➽ SA1195 Special Authority for Subsidy ❋ Three months or six months, as applicable, dispensed all-at-once 1 15 15 1 15 ml OP ✔ Hospira ✔ Uromitexan ✔ Uromitexan ✔ Arrow ✔ Poly-Tears

152 185 208

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

27


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013

29 BLOOD KETONE DIAGNOSTIC TEST METER a) Meter funded for the purposes of blood ketone diagnostics only. Patient has had one or more episodes of ketoacidosis and is at risk of future episodes. Only one meter per patient will be subsidised every 5 years. b) Up to 1 dev available on a PSO. Meter ..................................................................................... 40.00 1 ✔ Freestyle Optium KETONE BLOOD BETA-KETONE ELECTRODES a) Maximum of 20 strip per prescription. b) Up to 10 test available on a PSO. Test strip – Not on a BSO ........................................................ 15.50

29

10 strip OP ✔ Freestyle Optium Ketone

29

BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement a) Maximum of 1 pack per prescription. b) Up to 1 dev available on a PSO. c) A diagnostic blood glucose test meter is subsidised for a patient who: i is receiving insulin or sulphonylurea therapy; or ii is pregnant and has diabetes; or iii is on home TPN at risk of hypoglycaemia or hyperglycaemia; or iv has a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome. d) CareSens N brand: Brand switch fee payable (Pharmacode 2423138) - see page 186 for details e) CareSens N POP brand: Brand switch fee payable (Pharmacode 2423154) - see page 186 for details f) CareSens II brand: Brand switch fee payable (Pharmacode 2423146) - see page 186 for details g) No patient co-payment payable Only one CareSens meter per patient. No further prescriptions will be subsidised for patients who already have a CareSens meter. For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a CareSens meter. The prescription must be endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylureas. Meter with 50 lancets, a lancing device and 10 diagnostic test strips – Note differing brand requirements ............................ 20.00 1 OP ✔ CareSens II ✔ CareSens N ✔ CareSens N POP Note: Only 1 meter available per PSO

30

BLOOD GLUCOSE DIAGNOSTIC TEST STRIP a) Up to 50 test available on a PSO. b) The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; or 4) Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or 5) Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements below ........................... 10.56 50 test OP ✔ CareSens ✔ CareSens N continued...

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

28

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

continued... 28.75 a) Accu-Chek Performa brand: Special Authority see SA1294 – Retail pharmacy b) Freestyle Optium brand: Special Authority see SA1291 – Retail pharmacy Note: Accu-Chek Performa and Freestyle Optium are not available on a PSO URSODEOXYCHOLIC ACID – Special Authority see SA1383 1188 – Retail pharmacy Cap 250 mg – For ursodeoxycholic acid oral liquid formulation refer, page 188 .................................................. 71.50 100 ✔ Accu-Chek Performa ✔ Freestyle Optium

38

✔ Ursosan

➽ SA1383 1188 Special Authority for Subsidy Initial application – (Alagille syndrome or progressive familial intrahepatic cholestasis) - from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1. Patient has been diagnosed with Alagille syndrome; or 2. Patient has progressive familial intrahepatic cholestasis. Initial application – (Chronic severe drug induced cholestatic liver injury) - from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1. Patient has chronic severe drug induced cholestatic liver injury; and 2. Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and 3. Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay. Initial application – (Cirrhosis) - from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1. Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 2. Patient not requiring a liver transplant (bilirubin > 170 100 umol/l; decompensated cirrhosis). Initial application – (Pregnancy/Cirrhosis) - from any relevant practitioner. Approvals valid for 6 months where the Either: patient diagnosed with cholestasis of pregnancy.; or 1. Both: 1.1. Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and 1.2. Patient not requiring a liver transplant (bilirubin > 170 100 umol/l; decompensated cirrhosis) Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease. Initial application – (Haematological transplant) - from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1. Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and 2. Treatment for up to 13 weeks. Initial application – (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1. Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and 2. Liver function has not improved with modifying the TPN composition. continued...

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

29


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

continued... Renewal (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment. Renewal – (Pregnancy/cirrhosis) - from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where a paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels. Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 100 µmol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation. 38 47 MUCILAGINOUS LAXATIVES ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription ❋ Dry Powder for oral soln........................................................... 5.51 500 g OP ✔ Konsyl-D PROTAMINE SULPHATE ❋ Inj 10 mg per ml, 5 ml ............................................................ 22.40 (101.61) QUINAPRIL – Brand switch fee payable (Pharmacode 2441497) ❋ Tab 5 mg ................................................................................. 3.44 ❋ Tab 10 mg ............................................................................... 4.64 ❋ Tab 20 mg ............................................................................... 6.34 CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL ❋ Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs – Up to 84 tab available on a PSO ........................................ 3.89 10 Artex S29 90 90 90 ✔ Arrow-Quinapril 5 ✔ Arrow-Quinapril 10 ✔ Arrow-Quinapril 20

52 78 80

84

✔ Ginet 84

SOLIFENACIN SUCCINATE – Special Authority see SA0998 – Retail pharmacy Tab 5 mg ............................................................................... 56.50 30 ✔ Vesicare Tab 10 mg .............................................................................. 56.50 30 ✔ Vesicare ➽ SA0998 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal, unless notified, where the patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin. TOLTERODINE – Special Authority see SA1272 – Retail pharmacy Tab 1 mg ............................................................................... 14.56 Tab 2 mg ................................................................................ 14.56 56 56 ✔ Arrow-Tolterodine ✔ Arrow-Tolterodine

80

➽ SA1272 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal, unless notified, where the patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin. 82 85 PREDNISONE Tab 1 mg ............................................................................... 10.68 500 ✔ Apo-Prednisone Note: the removal of the stat symbol will be temporary due to a potential out of stock PROPYLTHIOURACIL – Special Authority see SA1199 – Retail pharmacy Tab 50 mg .............................................................................. 35.00 100 ✔ PTU S29 Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

30


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

86 CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA1370 1031 ........... 6.25 25.00 ➽ SA1370 1031 Special Authority for Waiver of Rule 2 8 ✔ Dostinex ✔ Dostinex

Initial application only from an obstetrician, endocrinologist or any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria where the patient has: 1) pathological hyperprolactinemia; or 2) acromegaly*. Renewal (for patients who have previously been funded under Special Authority form SA1031) only from an obstetrician, endocrinologist or gynaecologist any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment. Indication marked with * is an Unapproved Indication. 86 DANAZOL – Retail pharmacy-Specialist Cap 100 mg ........................................................................... 68.33 Cap 200 mg ........................................................................... 97.83 100 100 ✔ Azol ✔ Azol

88

CEFAZOLIN SODIUM – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient cellulitis in accordance with a DHB approved protocol and the prescription is endorsed accordingly. Inj 500 mg ................................................................................ 3.99 5 ✔ AFT Inj 1 g ....................................................................................... 3.99 5 ✔ AFT CEFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of confirmed ciprofloxacin-resistant gonorrhoea, or the treatment of pelvic inflammatory disease, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly. Inj 500 mg ................................................................................ 2.70 1 ✔ Veracol Inj 1 g ..................................................................................... 10.49 5 ✔ Aspen Ceftriaxone MINOCYCLINE HYDROCHLORIDE ❋ Tab 50 mg – Additional subsidy by Special Authority see SA1355 – Retail pharmacy ................ 5.79 60 (12.05) Mino-tabs ➽ SA1355 Special Authority for Manufacturers Price Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has rosacea. GENTAMICIN SULPHATE Inj 10 mg per ml, 1 ml – Subsidy by endorsement ..................... 8.56 5 ✔ Mayne Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis or complicated urinary tract infection, and the prescription is endorsed accordingly. Inj 10 mg per ml, 2 ml – Subsidy by endorsement ................ 175.10 25 ✔ APP Pharmaceuticals

S29

88

91

92

Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis or complicated urinary tract infection, and the prescription is endorsed accordingly. Inj 40 mg per ml, 2 ml – Subsidy by endorsement ..................... 6.50 10 ✔ Pfizer Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis or complicated urinary tract infection, and the prescription is endorsed accordingly.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

31


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

92 MOXIFLOXACIN – Special Authority see SA1358 1065 – Retail pharmacy No patient co-payment payable Tab 400 mg ........................................................................... 52.00

5

✔ Avelox

➽ SA1358 1065 Special Authority for Subsidy Initial application - (Mycoplasma genitalium) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: All of the following: 1. Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium*; and 2. Has tried and failed to clear infection using azithromycin; and 3. Treatment is only for 7 days. Initial application - (Penetrating eye injury) only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only. Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 4.6). 93 VANCOMYCIN HYDROCHLORIDE – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient or in the treatment of pseudomembranous colitis or for prophylaxis of endocarditis or for treatment of Clostridium difficile following metronidazole failure and the prescription is endorsed accordingly. Inj 500 mg ............................................................................... 3.58 1 ✔ Mylan FLUCONAZOLE Powder for oral suspension 10 mg per ml – Special Authority see SA1359 1148– Retail pharmacy ...... 34.56

94

35 ml

✔ Diflucan

➽ SA1359 1148 Special Authority for Subsidy Initial application – (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria: Both: 1. Patient requires prophylaxis for, or treatment of systemic candidiasis; and 2. Patient is unable to swallow capsules. Initial application – (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1. Patient is immunocompromised; and 2. Patient is at moderate to high risk of invasive fungal infection; and 3. Patient is unable to swallow capsules. Renewal – (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria: Both: 1. Patient requires prophylaxis for, or treatment of systemic candidiasis; and 2. Patient is unable to swallow capsules. Renewal – (Immunocompromised) from any relevant practitioner. Approvals valid for 6 month for applications meeting the following criteria: All of the following: 1. Patient remains immunocompromised; and 2. Patient remains at moderate to high risk of invasive fungal infection; and 3. Patient is unable to swallow capsules.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

32

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

98 LAMIVUDINE – Special Authority see SA1360 0832– Retail pharmacy Tab 100 mg ............................................................................ 32.50 Oral liq 5 mg per ml ................................................................ 90.00 28 240 ml ✔ Zetlam ✔ Zeffix

➽ SA1360 0832 Special Authority for Subsidy Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician or on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1.1 All of the following: 1.1.1 HBsAg positive for more than 6 months; and 1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and 1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology or clinical/radiological evidence of cirrhosis; or 21 HBV DNA positive cirrhosis prior to liver transplantation; or 32 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or 43 Hepatitis B virus naïve patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or 4 Hepatitis B surface antigen (HbsAg) positive patient who is receiving chemotherapy for a malignancy, or high dose steroids (at least 20mg/day for at least 7 days) or who has received such treatment within the previous two months; or 5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or 6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP). 2. All of the following: 2.1. No continuing alcohol abuse or intravenous drug use; and 2.2. Not coinfected with HCV or HDV; and 2.3. Neither ALT nor AST greater than 10 times upper limit of normal; and 2.4. No history of hypersensitivity to lamivudine; and 2.5. No previous lamivudine therapy with genotypically proven lamivudine resistance. Renewal only from a gastroenterologist, infectious disease specialist, paediatrician or general physician or on the recommendation of a gastroenterologist, infectious disease specialist. paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: Renewal for patients who have maintained continuous treatment and response to lamivudine 1. All of the following: 1.1. Have maintained continuous treatment with lamivudine; and 1.2. Most recent test result shows continuing biochemical response (normal ALT); and 1.3. HBV DNA < 100,000 copies per ml by quantitative PCR at a reference laboratory. Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine 2. All of the following 2.1. lamivudine to be used in combination with adefovir dipivoxil; and 2.2. patient is cirrhotic; and Documented resistance to lamivudine, defined as: 2.3. patient has raised serum ALT (> 1 x ULN); and 2.4. patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and 2.5. detection of M204I or M204V mutation. Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil 3. All of the following 3.1. lamivudine to be used in combination with adefovir dipivoxil; and Documented resistance to adefovir, defined as: continued...

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

33


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

continued... 3.2. patient has raised serum ALT (> 1 x ULN); and 3.3. patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and 3.4. detection of N236T or A181T/V mutation 30 ✔ Baraclude

98

ENTECAVIR – Special Authority see SA1361 0977 – Retail pharmacy Tab 0.5 mg ........................................................................... 400.00

➽ SA1361 0977 Special Authority for Subsidy Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and 3 Entecavir dose 0.5 mg/day; and 4 Either: 4.1 ALT greater than upper limit of normal; or 4.2 Bridging fibrosis (Metavir stage 3 or greater or moderate fibrosis) or cirrhosis on liver histology; and 5 Either: 5.1 HBeAg positive; or 5.2 patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and 6 No continuing alcohol abuse or intravenous drug use; and 7 Not co-infected with HCV, HIV or HDV; and 8 Neither ALT nor AST greater than 10 times upper limit of normal; and 9 No history of hypersensitivity to entecavir; and 10 No previous documented lamivudine resistance (either clinical or genotypic). Notes: • Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4). • Entecavir should be taken on an empty stomach to improve absorption 100 TENOFOVIR DISOPROXIL FUMARATE – Subsidy by endorsement; can be waived by Special Authority see SA1362 1047 Endorsement for treatment of HIV/AIDS: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1364 1025 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber. Note: Tenofovir disoproxil fumarate prescribed under endorsement for the treatment of HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1364 1025. Tab 300 mg .......................................................................... 531.00 30 ✔ Viread ➽ SA1362 1047 Special Authority for Waiver of Rule Initial application - (Chronic Hepatitis B) Only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal, unless notified, for applications meeting the following criteria: Any of the following 1. Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and 1.1. All of the following 1.1.1. Patient has had previous lamivudine, adefovir or entecavir therapy; and 1.1.2. HBV DNA greater than 20,000 IU/mL or increased = 10 fold over nadir; and 1.1.3. Any of the following: 1.1.3.1. Lamivudine resistance - detection of M204I/V mutation; or 1.1.3.2. Adefovir resistance - detection of A181T/V or N236T mutation; or continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

34


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

continued... Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or 2. Patient is either listed or has undergone liver transplantation for HBV; or 3. Patient has decompensated cirrhosis with a Mayo score >20. 1.1.3.3.

Initial application - (Pregnant, active hepatitis B) only from a gastroenterologist, infectious disease physician or general physician. Approvals valid for 12 months 4 months for applications meeting the following criteria: Both: 1 Patient is HBsAg positive and pregnant; and 2 Either: 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or 2.2 HBV DNA > 100 million IU/mL and ALT normal. Renewal - (Subsequent Pregnancy or breastfeeding, active hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months 4 months for applications meeting the following criteria: Both: 1 Patient is HBsAg positive and pregnant or breastfeeding; and 2 Either: 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or 2.2 HBV DNA > 100 million IU/mL and ALT normal. Initial application - (Pregnant, prevention of vertical transmission) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months 4 months for applications meeting the following criteria: Both: 1 Patient is HBsAg positive and pregnant; and 2 Either: 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or 2.2 HBV DNA > 100 20 million IU/mL and ALT normal. Renewal - (Subsequent pregnancy, prevention of vertical transmission) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months 4 months for applications meeting the following criteria: Both: 1 Patient is HBsAg positive and pregnant; and 2 Either: 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or 2.2 HBV DNA > 100 20 million IU/mL and ALT normal. 100 VALACICLOVIR – Special Authority see SA1363 0957 – Retail pharmacy Tab 500 mg ......................................................................... 102.72 ➽ SA1363 0957 Special Authority for Subsidy Initial application – (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily. Renewal – (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. Initial application – (ophthalmic zoster) from any medical practitioner. Approvals valid without further renewal unless notified where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment. Initial application – (CMV prophylaxis) from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation. continued...

30

✔ Valtrex

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

35


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

continued... Initial application – (immunocompromised patients) from any medical practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patients is immunocompromised; and 2 Patient has herpes zoster; and 3 Valaciclovir is to be given for a maximum of 7 days per course. 102 ANTIRETROVIRALS ➽ SA1364 1025 Special Authority for Subsidy Initial application – (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Confirmed HIV infection; and 2 Any of the following: 2.1 Symptomatic patient; or 2.2 Patient aged 12 months and under; or 2.3 Both: 2.3.1 Patient aged 1 to 5 years; and 2.3.2 Any of the following: 2.3.2.1 CD4 counts < 1000 cells/mm3; or 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or 2.3.2.3 Viral load counts > 100000 copies per ml; or 2.4 Both: 2.4.1 Patient aged 6 years and over; and 2.4.2 CD4 counts < 350500 cells/mm3. Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals. Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals. Renewal — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Prevention of maternal foetal transmission; or 2 Treatment of the newborn for up to eight weeks. Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals. Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals. Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated. Initial application – (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both: 1 Treatment course to be initiated within 72 hours post exposure; and 2 Either: continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

36


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

continued... 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals. Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals. Renewal – (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both: 1 Treatment course to be initiated within 72 hours post exposure; and 2 Either: 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required Initial application – (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive. Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals. Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals. Renewal – (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive. 105 Guidelines for the use of interferon in the treatment of hepatitis C: Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit. Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level. Criteria for Treatment a) Diagnosis - Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or - PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or - Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following. b) Establishing Active Chronic Liver Disease - Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six months averaging > 1.5 x upper limit of normal. (ALT is the preferable enzyme); or - Liver biopsy showing significant inflammatory activity (active hepatitis) with or without cirrhosis. This is not a necessary requirement for those patients with coagulopathy. (Some patients have active disease on histology with normal transaminase enzymes). Exclusion Criteria a) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease). b) Pregnancy. c) Neutropenia (<2.0 x 109) and/or thrombocytopenia. d) Continuing alcohol abuse and/or continuing intravenous drug users. continued...

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

37


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

continued... Dosage The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2b administered subcutaneously three times a week for 52 weeks (twelve months). Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pretreatment ALT level at this stage. 107 PEGYLATED INTERFERON ALPHA-2A – Special Authority see SA1365 1134 – Retail pharmacy See prescribing guideline Inj 135 mcg prefilled syringe ................................................. 362.00 1 ✔ Pegasys 1,448.00 4 ✔ Pegasys Inj 180 mcg prefilled syringe . ................................................ 450.00 1 ✔ Pegasys 1,800.00 4 ✔ Pegasys Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 ............................. 1,799.68 1 OP ✔ Pegasys RBV Combination Pack Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 .............................. 1,975.00 1 OP ✔ Pegasys RBV Combination Pack Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 .............................. 2,059.84 1 OP ✔ Pegasys RBV Combination Pack Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 168 ............................. 2,190.00 1 OP ✔ Pegasys RBV Combination Pack ➽ SA1365 1134 Special Authority for Subsidy Initial application – (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: Both: 1 Any of the following: Either: 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 1.2 Patient has chronic hepatitis C and is co-infected with HIV; and or 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and 2 Maximum of 48 weeks therapy. Notes: • Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure. • Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50 IU/ml) AND Baseline serum HCV RNA is less than 400,000 IU/ml Initial application – (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2 Maximum of 6 months therapy. Initial application – (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria: All of the following: continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

38


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

continued... 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B treatment-naive; and 3 ALT > 2 times Upper Limit of Normal; and 4 HBV DNA < 10 log10 IU/ml; and 5 Either: 5.1 HBeAg positive; or 5.2 serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and 6 Compensated liver disease; and 7 No continuing alcohol abuse or intravenous drug use; and 8 Not co-infected with HCV, HIV or HDV; and 9 Neither ALT nor AST > 10 times upper limit of normal; and 10 No history of hypersensitivity or contraindications to pegylated interferon; and 11 Maximum of 48 weeks therapy. Notes: • Approved dose is 180 mcg once weekly. • The recommended dose of Pegylated Interferon-alpha 2a is 180 mcg once weekly. • In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alpha 2a dose should be reduced to 135 mcg once weekly. • In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines. • Pegylated Interferon-alpha 2a is not approved for use in children. 119 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO ............ 35.60 6.90 SUMATRIPTAN Inj 12 mg per ml, 0.5 ml cartridge – Maximum of 10 inj per prescription ................................... 13.80 50 25 ✔ Xylocaine ✔ Lidocaine-Claris

130

2 OP

✔ Arrow-Sumatriptan

131

HYOSCINE (SCOPOLAMINE) – Special Authority see SA1387 0939 – Retail pharmacy Patch 1.5 mg ......................................................................... 11.95 2 ✔ Scopoderm TTS ➽ SA1387 0939 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: Either: 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or and 2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective. 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and 3 The applicant must specify the underlying malignancy or chronic disease. Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

39


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

166 ADALIMUMAB – Special Authority see SA1371 1156 – Retail pharmacy Inj 20 mg per 0.4 ml prefilled syringe .................................. 1,799.92 2 Inj 40 mg per 0.8 ml prefilled pen ...................................... 1,799.92 2 Inj 40 mg per 0.8 ml prefilled syringe .................................. 1,799.92 2 Note: Only the new criteria is listed below existing criteria remains unchanged. ✔ Humira ✔ HumiraPen ✔ Humira

➽ SA1371 1156 Special Authority for Subsidy Initial application - (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from etanercept; or 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for juvenile idiopathic arthritis; or 2 All of the following: 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2.2 Patient diagnosed with JIA; and 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and 2.5 Both: 2.5.1 Either: 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and 2.5.2 Physician's global assessment indicating severe disease. Initial application – (fistulising Crohn’s disease) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: 1 Patient has confirmed Crohn’s disease; and 2 Either 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or 2.2 Patient has one or more rectovaginal fistula(e); and 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application; and 4 The patient will be assessed for response to treatment after 4 months’ adalimumab treatment (see Note). Note: a maximum of 4 months’ adalimumab will be subsidised on an initial Special Authority approval for fistulising Crohn’s disease. Renewal – (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a named specialist or rheumatologist; or continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

40


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

continued... 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 3 Either: 3.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement inactive joint count and continued improvement in physician's global assessment from baseline.

Renewal – (fistulising Crohn’s disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months meeting the following criteria: Both: 1 Either: 1.1 Applicant is a gastroenterologist; or 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Either: 2.1 The number of open draining fistulae have decreased from baseline by at least 50%; or 2.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain. 175 BEE VENOM ALLERGY TREATMENT – Special Authority see SA1368 0053 – Retail pharmacy Maintenance kit - 6 vials 120 mcg freeze dried venom, 6 diluent 1.8 ml ................................................................ 285.00 1 OP ✔ Albay Treatment kit - Inj 1 vial 550 mcg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml ........................................... 285.00 1 OP ✔ Albay ➽ SA1368 0053 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising agent. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. 175 WASP VENOM ALLERGY TREATMENT – Special Authority see SA1367 0053 – Retail pharmacy Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml ..............285.00 1 OP ✔ Albay Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml ..............285.00 1 OP ✔ Albay ➽ SA1367 0053 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising agent. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

41


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

196 CARBOHYDRATE ➽ SA1373 1091 Special Authority for Subsidy nitial application – (Cystic fibrosis or kidney disease renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic kidney disease renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient Initial application – (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 faltering growth in an infant/child; or failure to thrive; or growth deficiency; or 4 bronchopulmonary dysplasia; or 5 premature and post premature infant; or 6 inborn errors of metabolism; or 7 for use as a component in a modular formula. 196 CARBOHYDRATE AND FAT ➽ SA1376 1091 Special Authority for Subsidy Initial application – (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 infant or child aged four years or under; and 2 cystic fibrosis. Initial application – (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Infant or child aged four years or under; and 2 Any of the following: 2.1 cancer in children; or 2.2 faltering growth; or failure to thrive; or growth deficiency; or 2.3 bronchopulmonary dysplasia; or 2.4 premature and post premature infants. 197 FAT ➽ SA1374 1092 Special Authority for Subsidy Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 faltering growth in an infant/child; or failure to thrive where other high calorie products are inappropriate or inadequate; or continued... growth deficiency; or

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

42


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

continued... 2 bronchopulmonary dysplasia; or 3 fat malabsorption; or 4 lymphangiectasia; or 5 short bowel syndrome; or 6 infants with necrotising enterocolitis; or 7 biliary atresia; or 8 for use in a ketogenic diet; or 9 chyle leak; or 10 acites; or 11 for use as a component in a modular formula. 198 PROTEIN ➽ SA1375 1093 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either: Any of the following: 1 protein losing enteropathy; or 2 high protein needs (eg burns); or 3 for use as a component in a modular formula. RESPIRATORY PRODUCTS ➽ SA1094 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg. FAT MODIFIED PRODUCTS ➽ SA1381 1096 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either: Any of the following: 1 Patient has metabolic disorders of fat metabolism; or 2 Patient has chylothorax a chyle leak; or 3 Modified as a modular feed for adults. HIGH PROTEIN PRODUCTS ➽ SA1378 1097 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Anorexia and weight loss; and 2 Either: 2.1 decompensating liver disease without encephalopathy; or 2.2 protein losing gastro-enteropathy Either: 1 decompensating liver disease without encephalopathy; or 2 protein losing gastro-enteropathy.

198

199

199

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

43


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

200 PAEDIATRIC PRODUCTS ➽ SA1379 1224 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Child is aged one to ten years; and 2 Any of the following: 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or 2.2 any condition causing malabsorption; or failure to thrive; or 2.3 faltering growth in an infant/child; or 2.4 increased nutritional requirements; or 2.5 the child is being transitioned from TPN or tube feeding to oral feeding. PAEDIATRIC PRODUCTS FOR CHILDREN WITH CHRONIC RENAL FAILURE ➽ SA1099 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease renal failure. RENAL PRODUCTS ➽ SA1101 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic renal failure kidney disease. SPECIALISED AND ELEMENTAL PRODUCTS ➽ SA1377 1102 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 malabsorption; or 2 short bowel syndrome; or 3 enterocutaneous fistulas; or pancreatitis. 4 eosinophilic oesophagitis; or 5 inflammatory bowel disease; or 6 patients with multiple food allergies requiring enteral feeding. RENAL ORAL FEED 1 KCAL/ML 2 KCAL/ML – Special Authority see SA1101 – Hospital pharmacy [HP3] Liquid ........................................................................................ 3.80 237 ml OP ✔ Suplena ADULT PRODUCTS HIGH CALORIE ➽ SA1195 Special Authority for Subsidy Note: Only the criteria that have been amended are shown. Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Any of the following: 1.1 any condition causing malabsorption; or failure to thrive; or 1.2 faltering growth in an infant/child; or 1.3 increased nutritional requirements; or 1.4 fluid restricted; and 2 other lower calorie products have been tried; and continued... 3 patient has substantially increased metabolic requirements or is fluid restricted.

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

200

201

202

203 208

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

44


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 July 2013 (continued)

212 EXTENSIVELY HYDROLYSED FORMULA – Special Authority see SA1380 1220 – Hospital pharmacy [HP3] Powder ................................................................................... 15.21 450 g OP ✔ Pepti Junior Gold Karicare Aptamil ➽ SA1380 1220 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Any of the following: 1 Both: 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and 1.2 Either: 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or 2 Severe malabsorption; or 3 Short bowel syndrome; or 4 Intractable diarrhea; or 5 Biliary atresia; or 6 Cholestatic liver diseases causing malsorption; or Chylous ascite; or Chylothorax; or 7 Cystic fibrosis; or 8 Proven fat malabsorption; or 9 Severe intestinal motility disorders causing significant malabsorption; or 10 Intestinal failure.

Effective 1 June 2013

29 ACARBOSE – Brand switch fee payable (Pharmacode 2433257) - see page 177 for details ❋ Tab 50 mg ................................................................................ 9.82 90 ✔ Accarb ❋ Tab 100 mg ............................................................................ 15.83 90 ✔ Accarb METOLAZONE – Special Authority see SA1323 – Retail pharmacy Tab 5 mg ............................................................................ CBS

58

50 1

➽ SA1323 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where used for applications meeting the following criteria: the treatment of patients with refractory heart failure who are intolerant or have not responded to loop diuretics and/or loop-thiazide combination therapy. Either: 1)For the treatment of heart failure in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers; or 2)For the treatment of heart failure, in patients in whom treatment with ACE inhibitors and/or angiotensin receptor blockers is not tolerated due to renal impairment. 72 ETHINYLOESTRADIOL WITH LEVONORGESTREL ❋ Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab – Up to 84 tab available on a PSO – Brand switch fee payable (Pharmacode 2427958) see page 177 for details ........................................................ 2.95 84

✔ Zaroxolyn S29 ✔ Metolazone S29

✔ Ava 20 ED

98

LAMIVUDINE – Special Authority see SA0832 – Retail pharmacy – Brand switch fee payable (Pharmacode 2433257) - see page 177 for details Tab 100 mg ............................................................................ 32.50 28 ✔ Zetlam Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. ❋ Three months or six months, as applicable, dispensed all-at-once

45


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2013 (continued)

118 131 ENTACAPONE – Brand switch fee payable (Pharmacode 2433249) - see page 177 for details s Tab 200 mg............................................................................ 47.92 100 ✔ Entapone METOCLOPRAMIDE HYDROCHLORIDE ❋ Tab 10 mg – For metoclopramide oral liquid formulation refer, page 188 .............................................................................. 3.95 CHLORAMPHENICOL Eye drops 0.5% ........................................................................ 1.20 Funded for use in the ear* Indications marked with* are Unapproved Indications.

100 10 ml OP

✔ Metamide ✔ Chlorafast

182

182

EYE PREPARATIONS Eye preparations are only funded for use in the eye, unless explicitly stated otherwise. The exception is pilocarpine eye drops 1%, 2% and 4% which are subsidised for oral use pursuant to the Standard Formulae. PILOCARPINE Eye drops 4% - Subsidised for oral use pursuant to the Standard Formulae .............................................................. 7.99

184

15 ml OP

✔ Isopto Carpine

Effective 1 May 2013

52 PERINDOPRIL Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer’s surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%." ❋ Tab 2 mg – Higher subsidy of $18.50 per 30 tab with Endorsement .................................................................. 3.75 30 ✔ Apo-Perindopril (18.50) Coversyl ❋ Tab 4 mg – Higher subsidy of $25.00 per 30 tab with Endorsement .................................................................. 4.80 30 ✔ Apo-Perindopril (25.00) Coversyl

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

46

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 May 2013 (continued)

52 TRANDOLAPRIL Higher subsidy by endorsement is available Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors trandolapril for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%." For the purposes of this endorsement, congestive heart failure includes patients post myocardial infarction with an ejection fraction of less than 40%. Patients who started on trandolapril after 1 June 1998 are not eligible for full subsidy by endorsement. ❋ Cap 1 mg – Higher subsidy of $18.67 per 28 cap with Endorsement .................................................................. 3.06 28 (18.67) Gopten ❋ Cap 2 mg – Higher subsidy of $27.00 per 28 cap with Endorsement .................................................................. 4.43 28 (27.00) Gopten DILTIAZEM HYDROCHLORIDE ❋ Cap long-acting 120 mg – Brand switch fee payable (Pharmacode 2437775) .......... 31.83 ❋ Cap long-acting 180 mg – Brand switch fee payable (Pharmacode 2437775) .......... 47.67 ❋ Cap long-acting 240 mg – Brand switch fee payable (Pharmacode 2437775) .......... 63.58

57 91

500 500 500

✔ Apo-Diltiazem CD ✔ Apo-Diltiazem CD ✔ Apo-Diltiazem CD

CIPROFLOXACIN – Subsidy by endorsement 1) Subsidised only if: a) Patient has: i) microbiologically confirmed and clinically significant pseudomonas infection; or ii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea; b) Prescription or PSO is written by, or on the recommendation of, an infectious disease physician or a clinical microbiologist; and 2) The prescription or PSO is endorsed accordingly. Recommended for patients with the any of the following: i) microbiologically confirmed and clinically significant pseudomonas infection; or ii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea; or Tab 250 mg – Up to 5 tab available on a PSO ............................ 2.20 28 ✔ Cipflox Tab 500 mg – Up to 5 tab available on a PSO ............................ 3.00 28 ✔ Cipflox 10.71 100 ✔ Cipflox Tab 750 mg .............................................................................. 5.15 28 ✔ Cipflox 5.52 30 ✔ Ciprofloxacin Rex

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

47


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 May 2013 (continued)

92 CLINDAMYCIN Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement – Retail pharmacy-Specialist .... 9.90 16 ✔ Clindamycin ABM Specialist must be an infectious disease physician or a clinical microbiologist Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy-Specialist...160.00 10 ✔ Dalacin C Prescriptions must be written by, or on the recommendation of, an infectious disease physician or a clinical microbiologist. ITRACONAZOLE Cap 100 mg – Subsidy by endorsement .................................... 4.25 15 ✔ Itrazole Funded for tinea vesicolor where topical treatment has not been successful and diagnosis has been confirmed by mycology, or for tinea unguium where terbinafine has not been successful in eradication or the patient is intolerant to terbinafine and diagnosis has been confirmed by mycology and the prescription is endorsed accordingly. Can be waived by endorsement - Retail pharmacy - Specialist. Specialist must be an infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist. ISONIAZID – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician ❋ Tab 100 mg ........................................................................... 20.00 100 ✔ PSM ❋ Tab 100 mg with rifampicin 150 mg ....................................... 90.04 100 ✔ Rifinah ❋ Tab 150 mg with rifampicin 300 mg ..................................... 179.57 100 ✔ Rifinah LIGNOCAINE HYDROCHLORIDE LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Viscous soln 2%...................................................................... 55.00 200 ml Inj 1%, 5 ml – Up to 5 inj available on a PSO ........................... 35.00 50 Inj 2%, 5 ml – Up to 5 inj available on a PSO ........................... 23.00 50 6.90 25 Inj 1%, 20 ml – Up to 5 inj available on a PSO .......................... 20.00 5 Inj 2%, 20 ml – Up to 5 inj available on a PSO .......................... 15.00 5 2.40 1 ✔ Xylocaine Viscous ✔ Xylocaine ✔ Xylocaine ✔ Lidocaine-Claris ✔ Xylocaine ✔ Xylocaine ✔ Lidocaine-Claris

94

96

119

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

48

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 August 2013

48 52 WARFARIN SODIUM ( subsidy) Note: Marevan and Coumadin are not interchangeable. ❋ Tab 1 mg .................................................................................. 6.86 ❋ Tab 3 mg .................................................................................. 9.70 ❋ Tab 5 mg ................................................................................ 11.75

100 100 100

✔ Marevan ✔ Marevan ✔ Marevan

PERINDOPRIL ( alternate subsidy) From 1 August 2013 to 30 September 2013 the Coversyl brand of perindopril will be funded by Endorsement to the level of the ex-manufacturer price listed in the Schedule for patients who were previously accessing the higher subsidy by endorsement for perindopril prior to 1 May 2013. ❋ Tab 2 mg – Higher subsidy of $18.50 per 30 tab with endorsement ......................................................................... 3.75 30 (18.50) Coversyl ❋ Tab 4 mg – Higher subsidy of $25.00 per 30 tab with endorsement ......................................................................... 4.80 30 (25.00) Coversyl NIFEDIPINE ( subsidy) ❋ Tab long-acting 20 mg .............................................................. 9.59 INDAPAMIDE ( subsidy) ❋ Tab 2.5 mg ............................................................................... 2.25 BETAMETHASONE DIPROPIONATE ( price) Crm 0.05% ............................................................................... 2.96 8.97 Crm 0.05% in propylene glycol base ......................................... 4.33 Oint 0.05% ................................................................................ 2.96 8.97 Oint 0.05% in propylene glycol base .......................................... 4.33 HYDROCORTISONE ( subsidy) ❋ Inj 100 mg vial ......................................................................... 4.99 a) Up to 5 inj available on a PSO b) Only on a PSO CEFALEXIN MONOHYDRATE ( subsidy) Cap 500 mg .............................................................................. 5.70 CLINDAMYCIN ( subsidy) Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement – Retail pharmacy - Specialist ................................................ 5.80 100 90 15 g OP 50 g OP 30 g OP 15 g OP 50 g OP 30 g OP 1 ✔ Nyefax Retard ✔ Dapa-Tabs

56 59 67

✔ Diprosone ✔ Diprosone ✔ Diprosone OV ✔ Diprosone ✔ Diprosone ✔ Diprosone OV ✔ Solu-Cortef

81

89 92

20

✔ Cephalexin ABM

16

✔ Clindamycin ABM

94

ITRACONAZOLE ( subsidy) Cap 100 mg – Subsidy by endorsement .................................... 2.99 15 ✔ Itrazole Funded for tinea vesicolor where topical treatment has not been successful and diagnosis has been confirmed by mycology, or for tinea unguium where terbinafine has not been successful in eradication or the patient is intolerant to terbinafine and diagnosis has been confirmed by mycology and the prescription is endorsed accordingly. Can be waived by endorsement - Retail pharmacy - Specialist Specialist must be an infectious disease physician, clinical microbiologist or dermatologist. Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. ❋ Three months or six months, as applicable, dispensed all-at-once

49


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 August 2013 (continued)

104 ZIDOVUDINE [AZT] – Special Authority see SA1364 – Retail pharmacy ( subsidy) Cap 100 mg .......................................................................... 152.25 100 ✔ Retrovir Oral liq 10 mg per ml .............................................................. 30.45 200 ml OP ✔ Retrovir COLCHICINE ( subsidy) ❋ Tab 500 mcg .......................................................................... 10.08 DANTROLENE ( subsidy) ❋ Cap 25 mg .............................................................................. 65.00 ❋ Cap 50 mg .............................................................................. 77.00 100 100 100 ✔ Colgout ✔ Dantrium ✔ Dantrium

116 117 133

HALOPERIDOL – Safety medicine; prescriber may determine dispensing frequency ( subsidy) Tab 500 mcg – Up to 30 tab available on a PSO......................... 6.23 100 ✔ Serenace Tab 1.5 mg – Up to 30 tab available on a PSO ........................... 9.43 100 ✔ Serenace Tab 5 mg – Up to 30 tab available on a PSO ............................ 29.72 100 ✔ Serenace Oral liq 2 mg per ml – Up to 200 ml available on a PSO ............ 23.84 100 ml ✔ Serenace Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 21.55 10 ✔ Serenace INTERFERON BETA-1-ALPHA – Special Authority see SA1062 ( subsidy) Inj 6 million iu prefilled syringe ............................................ 1,320.87 Inj 6 million iu per 0.5 ml pen injector ................................. 1,320.87 Inj 6 million iu per vial ......................................................... 1,320.87 4 4 4 ✔ Avonex ✔ Avonex Pen ✔ Avonex

139

145 149 151

NALTREXONE HYDROCHLORIDE – Special Authority see SA1397 – Retail pharmacy ( subsidy) Tab 50 mg ............................................................................. 76.00 30 ✔ Naltraccord MERCAPTOPURINE – PCT – Retail pharmacy-Specialist ( subsidy) Tab 50 mg ............................................................................. 49.41 DACARBAZINE – PCT only – Specialist ( subsidy) Inj 200 mg vial ........................................................................ 51.84 Inj 200 mg for ECP .................................................................. 51.84 MESNA – PCT only – Specialist ( subsidy) Tab 400 mg ......................................................................... 227.50 Tab 600 mg ......................................................................... 339.50 Inj 100 mg per ml, 4 ml ampoule ........................................... 148.05 Inj 100 mg per ml, 10 ml ampoule ......................................... 339.90 Inj 1 mg for ECP ........................................................................ 2.47 MITOMYCIN C – PCT only – Specialist ( subsidy) Inj 5 mg vial ........................................................................... 79.75 Inj 1 mg for ECP ...................................................................... 16.43 HYPROMELLOSE WITH DEXTRAN ( subsidy) ❋ Eye drops 0.3% with dextran 0.1% ............................................. 2.30 25 ✔ Puri-nethol

1 ✔ Hospira 200 mg OP ✔ Baxter 50 50 15 15 100 mg 1 1 mg 15 ml OP ✔ Uromitexan ✔ Uromitexan ✔ Uromitexan ✔ Uromitexan ✔ Baxter ✔ Arrow ✔ Baxter ✔ Poly-Tears

152

152

185

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

50

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 July 2013

28 INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE ( subsidy) s Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml ............................................................... 42.66 s Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml ................................................................................... 42.66 ISPAGUHULA (PHYLLIUM) HUSK – Only on a prescription ( subsidy) ❋ Powder for oral soln .................................................................. 5.51

5 5 500 g OP

✔ Humalog Mix 25 ✔ Humalog Mix 50 ✔ Konsyl-D

38 39

SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription ( subsidy) Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml ................................................................ 19.95 50 ✔ Micolette TERAZOSIN ( subsidy) ❋ Tab 1 mg .................................................................................. 0.50 ❋ Tab 2 mg .................................................................................. 0.45 ❋ Tab 5 mg .................................................................................. 0.68 CILAZAPRIL ( subsidy) ❋ Tab 0.5 mg ............................................................................... 2.00 ❋ Tab 2.5 mg ............................................................................... 4.31 ❋ Tab 5 mg .................................................................................. 6.98 CLONIDINE HYDROCHLORIDE ( subsidy) ❋ Tab 25 mcg ............................................................................ 13.47 SPIRONOLACTONE ( subsidy) ❋ Tab 25 mg ............................................................................... 3.65 ❋ Tab 100 mg ........................................................................... 11.80 EZETIMIBE – Special Authority see SA1045 – Retail pharmacy ( subsidy) Tab 10 mg ............................................................................. 34.43 28 28 28 90 90 90 100 100 100 30 ✔ Arrow ✔ Arrow ✔ Arrow ✔ Zapril ✔ Zapril ✔ Zapril ✔ Dixarit ✔ Spirotone ✔ Spirotone ✔ Ezetrol

51

51

57 58

60 60

EZETIMIBE WITH SIMVASTATIN – Special Authority see SA1046 – Retail pharmacy ( subsidy) Tab 10 mg with simvastatin 10 mg .......................................... 36.68 30 ✔ Vytorin Tab 10 mg with simvastatin 20 mg .......................................... 38.70 30 ✔ Vytorin Tab 10 mg with simvastatin 40 mg .......................................... 41.40 30 ✔ Vytorin Tab 10 mg with simvastatin 80 mg .......................................... 45.45 30 ✔ Vytorin FUSIDIC ACID ( subsidy) Oint 2% .................................................................................... 3.45 a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination LEVONORGESTREL ( subsidy) ❋ Tab 750 mcg............................................................................. 3.50 MEDROXYPROGESTERONE ACETATE ( subsidy) ❋ Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO ............................................. 7.00 Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. 15 g OP ✔ Foban

65

78 78

2

✔ Next Choice

1

✔ Depo-Provera

❋ Three months or six months, as applicable, dispensed all-at-once

51


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 July 2013 (continued)

92 CLINDAMYCIN ( subsidy) Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy-Specialist ............................................. 100.00 ACICLOVIR ( subsidy) ❋ Tab dispersible 200 mg ............................................................ 1.78 ❋ Tab dispersible 400 mg ............................................................. 5.98 ❋ Tab dispersible 800 mg ............................................................ 6.64 TETRABENAZINE ( subsidy) Tab 25 mg ........................................................................... 118.00 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE ( subsidy) Inj 2%, 5 ml – Up to 5 inj available on a PSO ............................ 13.80 Inj 2%, 20 ml – Up to 5 inj available on a PSO .......................... 12.00 DIHYDROCODEINE TARTRATE ( subsidy) Tab long-acting 60 mg ........................................................... 13.64 MORPHINE SULPHATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Tab long-acting 10 mg ............................................................ 1.95 Tab long-acting 30 mg .............................................................. 2.98 Tab long-acting 60 mg ............................................................. 5.75 Tab long-acting 100 mg ............................................................ 6.45 MORPHINE TARTRATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Inj 80 mg per ml, 1.5 ml ......................................................... 35.60 Inj 80 mg per ml, 5 ml .......................................................... 107.67 SERTRALINE ( subsidy) ❋ Tab 50 mg ................................................................................ 3.64 ❋ Tab 100 mg ............................................................................. 6.28 VENLAFAXINE – Special Authority see SA1061 – Retail pharmacy ( subsidy) Tab 37.5 mg ............................................................................. 7.84 Tab 75 mg .............................................................................. 13.94 Tab 150 mg ............................................................................ 17.08 Tab 225 mg ............................................................................ 27.14 Cap 37.5 mg ............................................................................. 8.71 Cap 75 mg .............................................................................. 17.42 Cap 150 mg ............................................................................ 21.35

10 25 56 35 112 50 5 60

✔ Dalacin C ✔ Lovir ✔ Lovir ✔ Lovir ✔ Motetis ✔ Xylocaine ✔ Xylocaine ✔ DHC Continus

99

119 119

120 122

10 10 10 10

✔ Arrow-Morphine LA ✔ Arrow-Morphine LA ✔ Arrow-Morphine LA ✔ Arrow-Morphine LA

122

5 5 90 90 28 28 28 28 28 28 28

✔ Hospira ✔ Hospira ✔ Arrow-Sertraline ✔ Arrow-Sertraline ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Arrow-Venlafaxine XR ✔ Efexor XR ✔ Efexor XR ✔ Efexor XR

124

125

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

52

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 July 2013 (continued)

130 SUMATRIPTAN ( subsidy) Tab 50 mg ................................................................................ 1.19 29.80 Tab 100 mg .............................................................................. 1.10 54.80 Inj 12 mg per ml, 0.5 ml cartridge – Maximum of 10 inj per prescription ................................... 13.80 4 100 2 100 2 OP ✔ Arrow-Sumatriptan ✔ Arrow-Sumatriptan ✔ Arrow-Sumatriptan ✔ Arrow-Sumatriptan ✔ Arrow-Sumatriptan

140

NITRAZEPAM – Safety medicine; prescriber may determine dispensing frequency ( subsidy) Tab 5 mg ................................................................................. 4.98 100 ✔ Nitrados ‡ Safety cap for extemporaneously compounded oral liquid preparations. NALTREXONE HYDROCHLORIDE – Special Authority see SA0909 – Retail pharmacy ( subsidy) Tab 50 mg .............................................................................. 79.00 30 ✔ Naltraccord METHOTREXATE ( subsidy) ❋ Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist ...... 20.20 ❋ Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist .... 27.78 DOCETAXEL – PCT only – Specialist ( subsidy) Inj 20 mg per ml, 1 ml ............................................................ 48.75 Inj 20 mg per ml, 4 ml .......................................................... 195.00 Inj 1 mg for ECP ....................................................................... 2.63 5 1 1 1 1 mg ✔ Hospira ✔ Hospira ✔ Taxotere ✔ Taxotere ✔ Baxter ✔ Temaccord ✔ Temaccord ✔ Temaccord ✔ Temaccord

145 149 151

153

TEMOZOLOMIDE – Special Authority see SA1063 – Retail pharmacy ( subsidy) Cap 5 mg .................................................................................. 8.00 5 Cap 20 mg .............................................................................. 36.00 5 Cap 100 mg .......................................................................... 175.00 5 Cap 250 mg ......................................................................... 410.00 5 VINCRISTINE SULPHATE ( subsidy) Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist ................................................ 64.80 Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist ................................................ 69.60 Inj 1 mg for ECP – PCT only – Specialist .................................... 9.45

154

5 5 1 mg

✔ Hospira ✔ Hospira ✔ Baxter

166

BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist ( subsidy) Subsidised only for bladder cancer. Inj 2-8 × 100 million CFU .................................................... 149.37 1 IPRATROPIUM BROMIDE ( subsidy) Nebuliser soln, 250 mcg per ml, 1 ml – Up to 40 neb available on a PSO ......................................... 3.26 Nebuliser soln, 250 mcg per ml, 2 ml – Up to 40 neb available on PSO ............................................ 3.37

✔ OncoTICE

178

20 20

✔ Univent ✔ Univent

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

53


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 June 2013

53 AMIODARONE HYDROCHLORIDE ( subsidy) Inj 50 mg per ml, 3 ml ampoule – Up to 6 inj available on a PSO..................................................................................... 22.80

6

✔ Cordarone-X

72

MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE ( subsidy) Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2%......................................................................... 11.15 90 g OP METYRAPONE ( subsidy) Cap 250 mg – Retail pharmacy-Specialist ............................. 520.00 PRAZIQUANTEL ( subsidy) Tab 600 mg ........................................................................... 68.00 METHYLCELLULOSE ( subsidy) Powder .................................................................................. 36.95 50 8 100 g

✔ Para Plus ✔ Metopirone ✔ Biltricide ✔ MidWest

87 88 193

Effective 1 May 2013

52 PERINDOPRIL ( subsidy) Tab 2 mg ................................................................................. 3.75 (18.50) Tab 4 mg .................................................................................. 4.80 (25.00) CALAMINE ( price) a) Only on a prescription b) Not in combination Crm, aqueous, BP .................................................................... 1.77 (3.80) LEVONORGESTREL ( subsidy) ❋ Tab 1.5 mg ............................................................................... 3.50 a) Maximum of 2 tab per prescription b) Up to 5 tab available on a PSO 30 Coversyl 30 Coversyl

66

100 g Home Essential 1 ✔ Postinor-1

78

120

CODEINE PHOSPHATE ( subsidy) – Safety medicine; prescriber may determine dispensing frequency Tab 15 mg ................................................................................ 4.75 100 ✔ PSM Tab 30 mg ................................................................................ 5.80 100 ✔ PSM Tab 60 mg .............................................................................. 12.50 100 ✔ PSM AMISULPRIDE ( subsidy) – Safety medicine; prescriber may determine dispensing frequency Tab 100 mg .............................................................................. 6.22 30 ✔ Solian Tab 200 mg ........................................................................... 21.92 60 ✔ Solian Tab 400 mg ........................................................................... 44.52 60 ✔ Solian Oral liq 100 mg per ml ............................................................ 52.50 60 ml ✔ Solian

132

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

54

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 August 2013

14 “Pharmacist Prescriber” means a person registered with the Pharmacy Council of New Zealand, who holds a current annual practising certificate under the HPCA Act 2003, and is approved by the Pharmacy Council of New Zealand to prescribe specified prescription medicines relating to his/her scope of practice. “Practitioner” means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber or an Optometrist or a Pharmacist Prescriber as those terms are defined in the Pharmaceutical Schedule. 3.1 Doctors’, Dentists’, Dietitians’, Midwives’, Nurse Prescribers’, and Optometrists’ and Pharmacist Prescribers’ Prescriptions (other than oral contraceptives) The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dentist, Dietitian, Midwife, Nurse Prescriber, or Optometrist or Pharmacist Prescriber unless specifically excluded: 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity sufficient to provide treatment for a period not exceeding three Months will be subsidised. 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate (except for Dentist prescriptions), only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised. 3.1.3 For a Class B Controlled Drug: a) other than Dentist prescriptions and methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity: i) sufficient to provide treatment for a period not exceeding 10 days; and ii) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised. b) for a Dentist prescription only such quantity as is necessary to provide treatment for a period not exceeding five days will be subsidised. 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dentist, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for: a) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot; b) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed: i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless: A) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or B) both: 1) the Practitioner endorses the Community Pharmaceutical on the Prescription with the words “certified exemption” written in the Practitioner’s own handwriting, or signed or initialled by the Practitioner; and 2) every Community Pharmaceutical endorsed as “certified exemption” is covered by Section F Part II of the Pharmaceutical Schedule.

14 16

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

55


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules – effective 1 August 2013 (continued)

17 3.2 Oral Contraceptives The following provisions apply to all Prescriptions written by a Doctor, Midwife, or Nurse Prescriber or Pharmacist Prescriber for an oral contraceptive: 3.2.1 The prescribing Doctor, Midwife, or Nurse Prescriber or Pharmacist Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed six Months. 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed: a) in Lots as specified in the Prescription if the Community Pharmaceutical is under the Dispensing Frequency Rule; or b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed. 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written. 3.2.4 Where a Community Pharmaceutical on a Prescription is under the Dispensing Frequency Rule and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy. 3.6 Pharmacist Prescribers’ Prescriptions The following apply to every prescription written by a Pharmacist Prescriber 3.6.1 Prescriptions written by a Pharmacist Prescriber for a Community Pharmaceutical will only be subsidised where they are for either: a) a Community Pharmaceutical classified as a Prescription Medicine and which a Pharmacist Prescriber is permitted under regulations to prescribe; or b) any other Community Pharmaceutical that is a Restricted Medicine (Pharmacist Only Medicine), a Pharmacy Only Medicine or a General Sales Medicine. 3.6.2 Any Pharmacist Prescribers’ prescriptions for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

19

Effective 1 July 2013

11 12 12 “Assessed Pharmaceuticals” means the list of Pharmaceuticals set out in Section H Part III of the Schedule, that have been or are being assessed by PHARMAC. “Optional Pharmaceuticals” means the list of National Contract Pharmaceuticals set out in Section H Part III of the Schedule. “Hospital Pharmaceuticals” means National Contract Pharmaceuticals, DV Pharmaceuticals, Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals. the list of Pharmaceuticals set out in Section H Part II of the Schedule which includes some National Contract Pharmaceuticals. “Community Pharmaceutical” means a Pharmaceutical listed in Section A to G and Section I of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community. “Discretionary Community Supply Pharmaceutical” means the list of Pharmaceuticals set out in Section H Part IV of the Schedule, which may be funded by a DHB Hospital from its own budget for use in the community.

12

12 12

“Hospital Pharmaceuticals in the Community (HPC)” means the pathway under the Named Patient Pharmaceutical Assessment policy to allow District Health Board hospitals to fund a medicine for a patient in the community if this is more affordable for the DHB than paying for the treatment that would otherwise need to be provided. Patients pay a manufacturer’s surcharge when S29 Unapproved medicine supplied under Section 29 the Manufacturer’s Price is greater than the Subsidy ‡ safety cap reimbursed Sole Subsidised Supply

56


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules – effective 1 July 2013 (continued)

14 16 19 “Practitioner” means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber or an Optometrist or a Pharmacist as those terms are defined in the Pharmaceutical Schedule. “Unlisted Pharmaceutical” means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical, but is not listed in Section H Part II. 3.6 Pharmacists’ prescriptions The following apply to every prescription written by a Pharmacist: 3.6.1 Prescriptions written by a Pharmacist for a Community Pharmaceutical will only be subsidised where theyare for the CareSens, CareSens N and CareSens N POP blood glucose diagnostic meters and annotated appropriately. 3.6.2 The prescribing and dispensing of blood glucose diagnostic meters by Pharmacists must be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.

Effective 1 May 2013

18 3.3 Original Packs, Certain Antibiotics and Unapproved Medicines 3.3.2 If a Community Pharmaceutical is either: a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981 excluding any medicine listed as Cost, Brand, Source of Supply, and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where: a) the difference the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100 ml pack would be dispensed); and b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner. Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

57


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules – effective 1 April 2013

13 “Hospital Pharmacy-Specialist” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either: a) on a Prescription signed by a Specialist, or b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either: i) endorsed with the words “recommended by [name of specialist and year of authorisation]” and signed by the Practitioner, or ii) endorsed with the word ‘protocol’ which means “initiated in accordance with DHB hospital approved protocol”, iii) annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words “recommended by [name of specialist and date of authorisation], confirmed by [practitioner]”. Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly. “As recommended by a Specialist” to be interpreted as either: 1) a) follows a substantive consultation with an appropriate Specialist; b) the consultation to relate to the Patient for whom the Prescription is written; c) consultation to mean communication by referral, telephone, letter, facsimile or email; d) except in emergencies consultation to precede annotation of the Prescription; and e) both the specialist and the General Practitioner must keep a written record of the consultation; or 2) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol 15 “Retail Pharmacy-Specialist” means that the Community Pharmaceutical is only eligible for Subsidy if it is either: a) supplied on a Prescription or Practitioner’s Supply Order signed by a Specialist, or, b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner’s Supply Order and either: i) endorsed with the words “recommended by [name of Specialist and year of authorisation]” and signed by the Practitioner, or ii) endorsed with the word ‘protocol’ which means “initiated in accordance with DHB hospital approved protocol”, or iii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words “recommended by [name of specialist and year of authorisation], confirmed by [practitioner]”. Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly. “As recommended by a Specialist” to be interpreted as either: 1) a) follows a substantive consultation with an appropriate Specialist; b) the consultation to relate to the Patient for whom the Prescription is written; c) consultation to mean communication by referral, telephone, letter, facsimile or email; d) except in emergencies consultation to precede annotation of the Prescription; and e) both the Specialist and the General Practitioner must keep a written record of consultation; or 2) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

58

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name

Effective 1 August 2013

149 MERCAPTOPURINE – PCT – Retail pharmacy-Specialist Tab 50 mg ............................................................................. 49.41 25 ✔ Purinethol Puri-nethol

Effective 1 July 2013

209 FOOD THICKENER – Special Authority see SA1106 – Hospital pharmacy [HP3] Powder ..................................................................................... 7.25 380 g OP ✔ Aptamil Feed Thickener Feed Thickener Karicare Aptamil

212

EXTENSIVELY HYDROLYSED FORMULA – Special Authority see SA1380 – Hospital pharmacy [HP3] Powder ................................................................................... 15.21 450 g OP ✔ Gold Pepti Junior Pepti Junior Gold Karicare Aptamil

Effective 1 June 2013

209 FOOD THICKENER – Special Authority see SA1106 – Hospital pharmacy [HP3] Powder ..................................................................................... 7.25 380 g OP ✔ Karicare Food Thickener Aptamil Feed Thickener

212

EXTENSIVELY HYDROLYSED FORMULA – Special Authority see SA1380 – Hospital pharmacy [HP3] Powder ................................................................................... 15.21 450 g OP ✔ Pepti Junior Gold Aptamil Gold Pepti Junior

Effective 1 May 2013

85 LEVOTHYROXINE Tab 50 mcg .............................................................................. 1.71 28 ✔ Goldshield Mercury Pharma ✔ Goldshield Mercury Pharma

‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 100 mcg............................................................................. 1.78 28 ‡ Safety cap for extemporaneously compounded oral liquid preparations.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

59


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Section I

Effective 1 May 2013

224 INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj ........................................................................................... 90.00 A) ✔ Fluarix ✔ Fluvax is available each year for patients who meet the following criteria, as set by PHARMAC: a) all people 65 years of age and over; b) people under 65 years of age with who: i) have the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) have the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii)are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness. iii)iv) have diabetes; iv)v) have chronic renal disease; v)vi) have any cancer, excluding basal and squamous skin cancers if not invasive; vi)vii)have any of the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) are children on long term aspirin; or vii)h)are pregnancy pregnant. c) people under 18 years of age living within the boundaries of the Canterbury District Health Board d) are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness Unless meeting other the criteria above, the following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease. Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule. Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. Stock of the seasonal influenza vaccine is typically available from February until late July with suppliers being required to ensure supply until at least 30 June. Exact start and end dates for each season will be notified each year. 10

B) C) D)

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

60

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Section E

Effective 1 July 2013

214 214 214 214 216 216 BLOOD GLUCOSE DIAGNOSTIC TEST METER ✔ Meter ..................................1 BLOOD KETONE DIAGNOSTIC TEST METER ✔ Meter ..................................1 BLOOD GLUCOSE DIAGNOSTIC TEST STRIP ✔ Test strip .............................50 strip CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL ✔ Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs ................84 KETONE BLOOD BETA-KETONE ELECTRODES ✔ Test strip .............................10 strip LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE ✔ Inj 1%, 5 ml .........................25 5

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

61


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 August 2013

103 145 ETRAVIRINE – Special Authority see SA1364 – Retail pharmacy Tab 100 mg ......................................................................... 770.00 BUPROPION HYDROCHLORIDE Tab modified-release 150 mg .................................................. 65.00 Note – This is the old Pharmacode for Zyban SALBUTAMOL ‡ Oral liq 2 mg per 5 ml ................................................................ 1.20 1.99 PHARMACY SERVICES - May only be claimed once per patient ❋ Brand switch fee........................................................................ 4.33 120 30 ✔ Intelence ✔ Zyban

178

90 ml 150 ml 1 fee

✔ Broncolin S29 ✔ Ventolin ✔ BSF Apo-Diltiazem CD

186 200

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1098 – Hospital pharmacy [HP3] Powder ................................................................................... 78.97 400 g OP ✔ Generaid Plus

Effective 1 July 2013

27 49 PANTOPRAZOLE ❋ Inj 40 mg .................................................................................. 6.50 DEXTROSE WITH ELECTROLYTES Soln with electrolytes................................................................. 6.60 6.75 QUINAPRIL ❋ Tab 5 mg .................................................................................. 1.15 ❋ Tab 10 mg ............................................................................... 1.55 ❋ Tab 20 mg ............................................................................... 2.11 PROPRANOLOL ❋ Tab 10 mg ............................................................................... 3.55 CALAMINE a) Only on a prescription b) Not in combination Crm, aqueous, BP .................................................................... 1.77 (3.80) METHYLPREDNISOLONE SODIUM SUCCINATE – Retail pharmacy-Specialist Inj 500 mg ............................................................................. 18.00 1 ✔ Pantocid IV

1,000 ml OP ✔ Pedialyte – Fruit ✔ Pedialyte – Plain 30 30 30 100 ✔ Accupril ✔ Accupril ✔ Accupril ✔ Cardinol

52 55 66

100 g Home Essential 1 ✔ Solu-Medrol

81 118

LEVODOPA WITH CARBIDOPA ❋ Tab 100 mg with carbidopa 25 mg – For levodopa with carbidopa oral liquid formulation refer, page 188 .................................. 20.00 100 ❋ Tab long-acting 200 mg with carbidopa 50 mg ........................ 47.50 100 ❋ Tab 250 mg with carbidopa 25 mg .......................................... 40.00 100 Note – new presentations of Sinement and Sinement CR were listed 1 January 2013.

✔ Sinemet ✔ Sinemet CR ✔ Sinemet

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

62

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 July 2013 (continued)

127 GABAPENTIN Cap 100 mg .............................................................................. 7.16 100 ✔ Nupentin Cap 300 mg ............................................................................ 11.50 100 ✔ Nupentin Note – the Nupentin capsules in the blister pack are delisted. The Nupentin capsules in bottles will remain listed as fully funded. PHARMACY SERVICES Brand switch fee........................................................................ 4.33 1 fee ✔ BSF Alphapharm ✔ BSF Nevirapine Alphapharm ✔ BSF Caresens II ✔ BSF Caresens N ✔ BSF Caresens N POP

186

212

AMINO ACID FORMULA – Special Authority see SA1219 below – Hospital pharmacy [HP3] Powder ................................................................................... 53.00 400 g OP ✔ Neocate

Effective 1 June 2013

53 AMIODARONE HYDROCHLORIDE Inj 50 mg per ml, 3 ml ampoule – Up to 6 inj available on a PSO..................................................................................... 60.84 BEZAFIBRATE ❋Tab 200 mg ............................................................................... 9.70 STAVUDINE [D4T] – Special Authority see SA1025 – Retail pharmacy Cap 30 mg ........................................................................... 377.80 DICLOFENAC SODIUM ❋Tab EC 25 mg ............................................................................ 1.63 ❋Tab EC 50 mg ........................................................................... 1.60 (2.13) DOMPERIDONE ❋Tab 10 mg – For domperidone oral liquid formulation refer, page 188 ............................................................................... 3.25 (11.99) PROMETHAZINE HYDROCHLORIDE ❋‡ Oral liq 5 mg per 5 ml ............................................................. 2.79 (3.10) PHARMACY SERVICES ❋Brand switch fee ........................................................................ 4.33

10 90 60 50 50

✔Cordarone-X ✔ Fibalip ✔ Zerit ✔ Diclofenac Sandoz Diclofenac Sandoz

59 104 109

130

100 Motilium 100 ml Promethazine Winthrop Elixir 1 fee ✔ BSF Accarb ✔ BSF Ava 20 ED ✔ BSF Entapone ✔ BSF Zetlam

176

186

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

63


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 May 2013

24 CALCIUM CARBONATE WITH AMINOACETIC ACID ❋ Tab 420 mg with aminoacetic acid 180 mg – Higher subsidy of $6.30 per 100 tab with Endorsement ......................................................................... 3.00 100 (6.30) Titralac Additional subsidy by endorsement is available for pregnant women. The prescription must be endorsed accordingly. MICONAZOLE Oral gel 20 mg per g ................................................................ 4.95 (8.70) RIVAROXABAN – Special Authority see SA1066 – Retail pharmacy Tab 10 mg ............................................................................ 306.00 DILTIAZEM HYDROCHLORIDE Cap long-acting 120 mg ............................................................ 1.91 (4.34) Cap long-acting 180 mg ........................................................... 2.86 (6.50) Cap long-acting 240 mg ........................................................... 3.81 (8.67) SILDENAFIL – Special Authority see SA1293 – Retail pharmacy Tab 25 mg ............................................................................. 39.00 Tab 50 mg ............................................................................. 43.50 Tab 100 mg – For sildenafil oral liquid formulation refer, page 179 ............................................................................. 47.00 CALCIPOTRIOL Oint 50 mcg per g .................................................................. 20.20 Soln 50 mcg per ml ................................................................ 33.79 4 4 4 30 g OP 60 ml OP 40 g OP Daktarin 30 ✔ Xarelto

40

47 57

Cardizem CD Cardizem CD Cardizem CD ✔ Viagra ✔ Viagra ✔ Viagra ✔ Daivonex ✔ Daivonex

63

72

89

AZITHROMYCIN – Maximum of 5 days treatment per prescription; can be waived by endorsement For Endorsement, patient has either: i) Received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome *; or ii) Cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms * Indications marked with * are Unapproved Indications Tab 500 mg – Up to 8 tab available on a PSO ............................ 1.25 2 OP ✔ Arrow-Azithromycin PAMIDRONATE DISODIUM Inj 3 mg per ml, 10 ml ............................................................ 16.00 (37.50) Inj 6 mg per ml, 10 ml ............................................................ 32.00 (75.00) Inj 9 mg per ml, 10 ml ............................................................ 48.00 (112.50) TYLOXAPOL ❋ Eye drops 0.25% ..................................................................... 8.63 1 Pamisol 1 Pamisol 1 Pamisol 15 ml OP ✔ Enuclene ✔ Neocate Advance

113

185 212

AMINO ACID FORMULA – Special Authority see SA1219 – Hospital pharmacy [HP3] Powder (tropical) .................................................................... 53.00 400 g OP

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

64

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 September 2013

198 206 FAT SUPPLEMENT – Special Authority see SA1374 – Hospital pharmacy [HP3] Oil .......................................................................................... 28.73 250 ml OP ✔ Liquigen ENTERAL FEED 1KCAL/ML – Special Authority see SA1228 – Hospital pharmacy [HP3] Liquid ........................................................................................ 2.65 500 ml OP ✔ Nutrison Standard RTH ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1228 – Hospital pharmacy [HP3] Liquid ....................................................................................... 2.65 500 ml OP ✔ Nutrison Multi Fibre

206

Effective 1 October 2013

45 SODIUM TETRADECYL SULPHATE ❋ Inj 0.5% 2 ml ...................................................................... 23.20 (51.00) ❋ Inj 1% 2 ml ......................................................................... 25.00 (55.00) CLONIDINE HYDROCHLORIDE ❋ Tab 25 mcg............................................................................. 13.47 CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail soln 8% ............................................................................ 19.85 LEVONORGESTREL ❋ Tab 750 mcg............................................................................. 3.50 5 Fibro-vein 5 Fibro-vein 100 ✔ Dixarit

57 65

3 g OP 2

✔ Batrafen ✔ Next Choice

78 88

CEFOXITIN SODIUM – Retail pharmacy-Specialist – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. Inj 1 g .................................................................................. 55.00 5 ✔ Mayne CEFUROXIME SODIUM Inj 250 mg – Maximum of 3 inj per prescription; can be waived by endorsement ....................................................... 20.97 10 ✔ Mayne Waiver by endorsement must state that the prescription is for dialysis or cystic fibrosis patient. Inj 1.5 g – Retail pharmacy-Specialist – Subsidy by endorsement ......................................................................... 2.65 1 ✔ Mylan 4.04 ✔ Zinacef Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly. FUSIDIC ACID Inj 500 mg sodium fusidate per 10 ml – Retail pharmacySpecialist – Subsidy by endorsement ................................... 12.87 1 (17.80) Fucidin Only if prescribed for a dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.

89

92

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

65


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 October 2013 (continued)

130 SUMATRIPTAN Tab 50 mg ................................................................................ 1.19 Tab 100 mg .............................................................................. 1.10 HOMATROPINE HYDROBROMIDE ❋ Eye drops 2% ............................................................................ 7.18 PHARMACY SERVICES ❋ Brand switch fee ....................................................................... 4.33 4 2 15 ml OP 1 fee ✔ Arrow-Sumatriptan ✔ Arrow-Sumatriptan ✔ Isopto Homatropine ✔ BSF Arrow-Quinapril

184 186

Effective 1 November 2013

181 211 SODIUM CROMOGLYCATE Nasal spray, 4% ..................................................................... 15.85 22 ml OP ✔ Rex

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 – Hospital pharmacy [HP3] Sachets (tropical) ................................................................. 324.00 30 ✔ Phlexy 10

Effective 1 December 2013

31 75 INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 31 g × 8 mm needle ................................ 13.00 100 ✔ ABM CONDOMS ❋ 53 mm extra strength – Up to 144 dev available on a PSO ......... 1.11 13.36 METHYLCELLULOSE Powder .................................................................................. 14.00 12 144 100 g ✔ Gold Knight ✔ Gold Knight

193

✔ ABM

Effective 1 January 2014

41 ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription ❋ Tab 100 mg ........................................................................... 13.80 VITAMIN B COMPLEX ❋ Tab, strong, BPC ....................................................................... 4.70 VITAMINS ❋ Tab (BPC cap strength) ............................................................ 8.00 MAGNESIUM SULPHATE ❋ Paste ........................................................................................ 2.98 (4.90)

500 500 1,000 80 g

✔ Vitala-C ✔ B-PlexADE ✔ MultiADE

41 42 74

PSM

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

66

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 January 2014 (continued)

83 OESTROGENS – See prescribing guideline Conjugated, equine tab 300 mcg .............................................. 3.01 28 (11.48) Conjugated, equine tab 625 mcg .............................................. 4.12 28 (11.48) Note: The old Pharmacodes are being delisted; Pharmacodes 2427478 and 2427486 will remain fully funded. AMOXYCILLIN Drops 125 mg per 1.25 ml ....................................................... 4.00 30 ml OP

Premarin Premarin

90

✔ Ospamox Paediatric Drops

92

LINCOMYCIN – Retail pharmacy-Specialist Prescriptions must be written by, or on the recommendation of, an infectious disease physician or a clinical microbiologist Inj 300 mg per ml, 2 ml .......................................................... 80.00 5 ✔ Lincocin GABAPENTIN – Special Authority see SA1071 – Retail pharmacy s Cap 400 mg ............................................................................ 14.75 100 ✔ Nupentin Note: This is the blister pack presentation only. The Nupentin capsules in the bottle will remain fully funded.

126

Effective 1 February 2014

24 42 86 DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE ❋ Tab 2.5 mg with atropine sulphate 25 mcg ............................... 3.90 CALCITRIOL ❋ Oral liq 1 mcg per ml .............................................................. 39.40 LEUPRORELIN Inj 3.75 mg .......................................................................... 221.60 Inj 11.25 mg ........................................................................ 591.68 100 10 ml OP 1 1 ✔ Diastop ✔ Rocaltrol solution ✔ Lucrin Depot ✔ Lucrin Depot

106

INTERFERON ALPHA-2A – PCT – Retail pharmacy-Specialist a) See prescribing guideline b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist Inj 6 m iu prefilled syringe ....................................................... 62.64 1 ✔ Roferon-A Inj 9 m iu prefilled syringe ........................................................ 93.96 1 ✔ Roferon-A QUETIAPINE – Safety medicine; prescriber may determine dispensing frequency Tab 100 mg ........................................................................... 14.00 60 DOCETAXEL – PCT only – Specialist Inj 20 mg ............................................................................... 48.75 Inj 80 mg .............................................................................. 195.00 CHLORAMPHENICOL Ear drops 0.5%.......................................................................... 2.20 Note – Chloramphenicol eye drops 0.5% are subsidised for use in the ear. ✔ Dr Reddy’s Quetiapine ✔ Docetaxel Ebewe ✔ Docetaxel Ebewe ✔ Chloromycetin

134

151

1 1 5 ml OP

182

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

67


Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 February 2014 (continued)

208 ORAL FEED 2 KCAL/ML – Special Authority see SA1195 – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly. Liquid (vanilla) – Higher subsidy of $2.25 per 237 ml with endorsement ........................................................................ 1.14 237 ml OP (2.25) Two Cal HN

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

68

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply


Index

Pharmaceuticals and brands A Acarbose ........................................................... 45 Accarb ............................................................... 45 Accu-Chek Performa .......................................... 29 Aciclovir ............................................................ 52 Aclasta .............................................................. 26 Adalimumab................................................. 22, 40 Adult products high calorie ........................... 27, 44 Albay ................................................................. 41 Alendronate for Osteoporosis ............................. 25 Accupril ............................................................. 62 Amiloride hydrochloride...................................... 21 Amino acid formula ...................................... 63, 64 Aminoacid formula without phenylalanine ..... 23, 66 Amiodarone hydrochloride............................ 54, 63 Amisulpride........................................................ 54 Antiretrovirals ..................................................... 36 Apo-Amiloride .................................................... 21 Apo-Diltiazem CD ......................................... 25, 47 Apo-Perindopril ............................................ 23, 46 Apo-Prednisone ........................................... 25, 30 Apo-Prednisone S29 .................................... 20, 25 Aptamil Feed Thickener ...................................... 59 Aptamil Gold Pepti Junior ................................... 59 Arrow-Morphine LA ............................................ 52 Arrow-Quinapril 5 ............................................... 30 Arrow-Quinapril 10 ............................................. 30 Arrow-Quinapril 20 ............................................. 30 Arrow-Sertraline ................................................. 52 Arrow-Sumatriptan ................................. 39, 53, 66 Arrow-Tolterodine .............................................. 30 Arrow-Venlafaxine XR......................................... 52 Artex .................................................................. 30 Ascorbic acid ............................................... 21, 66 Aspen Ceftriaxone .............................................. 31 Ava 20 ED.......................................................... 45 Avelox................................................................ 32 Avonex .............................................................. 50 Avonex Pen ........................................................ 50 Azithromycin ...................................................... 64 Azol ................................................................... 31 B Bacillus calmette-guerin (bcg) vaccine ............... 53 Baraclude .......................................................... 34 Batrafen ............................................................. 65 Bee venom allergy treatment .............................. 41 Betamethasone dipropionate .............................. 49 Bezafibrate ......................................................... 63 Biltricide............................................................. 54 Blood glucose diagnostic test meter ............. 28, 61 Blood glucose diagnostic test strip ............... 28, 61 Blood ketone diagnostic test meter ............... 28, 61 Bosentan ........................................................... 23 Bplex ................................................................. 21 B-PlexADE ......................................................... 66 Brilinta ............................................................... 21 Broncolin ........................................................... 62 BSF Accarb ........................................................ 63 BSF Alphapharm ................................................ 63 BSF Apo-Diltiazem CD .................................. 23, 62 BSF Arrow-Quinapril ..................................... 22, 66 BSF Ava 20 ED................................................... 63 BSF Caresens II.................................................. 63 BSF Caresens N ................................................. 63 BSF Caresens N POP ......................................... 63 BSF Entapone .................................................... 63 BSF Nevirapine Alphapharm ............................... 63 BSF Zetlam ........................................................ 63 Bupropion hydrochloride .............................. 20, 62 Buspirone hydrochloride..................................... 27 C Cabergoline........................................................ 31 Calamine...................................................... 54, 62 Calcitriol ............................................................ 67 Calcipotriol......................................................... 64 Calcium carbonate with aminoacetic acid ........... 64 Carbohydrate ..................................................... 42 Carbohydrate and fat .......................................... 42 Carbomer........................................................... 20 Cardinol ............................................................. 62 Cardizem CD ...................................................... 64 CareSens ........................................................... 28 CareSens II ........................................................ 28 CareSens N ........................................................ 28 CareSens N POP ................................................ 28 Cefalexin monohydrate ................................. 25, 49 Cefalexin Sandoz ................................................ 25 Cefazolin sodium ............................................... 31 Cefoxitin sodium ................................................ 65 Ceftriaxone sodium ............................................ 31 Cefuroxime sodium ............................................ 65 Cephalexin ABM ........................................... 25, 49 Cephalexin monohydrate .................................... 25 Cetomacrogol with glycerol ................................ 21 Chlorafast .......................................................... 46 Chloramphenicol .......................................... 46, 67 Chloromycetin.................................................... 67 Ciclopirox olamine.............................................. 65 Cilazapril ............................................................ 51 Cipflox ............................................................... 47 Ciprofloxacin ...................................................... 47 Ciprofloxacin Rex ............................................... 47

69


Index

Pharmaceuticals and brands Clindamycin ........................................... 48, 49, 52 Clindamycin ABM......................................... 48, 49 Clonidine BNM ................................................... 23 Clonidine hydrochloride .......................... 23, 51, 65 Condoms ........................................................... 66 Cordarone .......................................................... 54 Cordarone-X ...................................................... 63 Codeine phosphate ............................................ 54 Colchicine .......................................................... 50 Colgout .............................................................. 50 Coversyl .......................................... 25, 46, 49, 54 Cvite .................................................................. 21 Cyproterone acetate with ethinyloestradiol .... 30, 61 D Dantrolene ......................................................... 50 Dapa-Tabs ......................................................... 49 Depo-Provera ..................................................... 51 Diastop .............................................................. 67 Diclofenac Sandoz ............................................. 63 Diclofenac sodium ............................................. 63 Diltiazem hydrochloride .......................... 25, 47, 64 Diphenoxylate hydrochloride with atropine sulphate............................................. 67 Docetaxel ..................................................... 53, 67 Docetaxel Ebewe ................................................ 67 Domperidone ..................................................... 63 Dostinex ............................................................ 31 Dr Reddy’s Quetiapine .................................. 20, 67 Dacarbazine ................................................. 27, 50 Daivonex ............................................................ 64 Daktarin ............................................................. 64 Dalacin C ..................................................... 48, 52 Danazol.............................................................. 31 Dantrium ............................................................ 50 Dextrose with electrolytes................................... 62 DHC Continus .................................................... 52 Diflucan ............................................................. 32 Dihydrocodeine tartrate ...................................... 52 Diprosone .......................................................... 49 Diprosone OV..................................................... 49 Dixarit .......................................................... 51, 65 E Efexor XR ........................................................... 52 Entacapone ........................................................ 46 Entapone ........................................................... 46 Entecavir ............................................................ 34 Enteral feed 1kcal/ml .......................................... 65 Enteral feed with fibre 1 kcal/ml .......................... 65 Enteral/oral feed 1kcal/ml ................................... 62 Enuclene ............................................................ 64 Ethinyloestradiol with Levonorgestrel .................. 45 Etravirine............................................................ 62 Evista................................................................. 25 Extensively hydrolysed formula..................... 45, 59 Ezetimibe ........................................................... 51 Ezetimibe with simvastatin ................................. 51 Ezetrol ............................................................... 51 F Fat ..................................................................... 42 Fat modified products......................................... 43 Fat supplement ............................................ 22, 65 Feed Thickener Karicare Aptamil ......................... 59 Fentanyl ............................................................. 26 Fentanyl citrate................................................... 26 Fibalip ................................................................ 63 Fibro-vein........................................................... 65 Fluarix ................................................................ 60 Fluconazole ........................................................ 32 Fluvax ................................................................ 60 Foban ................................................................ 51 Food thickener ................................................... 59 Food Thickener .................................................. 59 Freestyle Optium .......................................... 28, 29 Freestyle Optium Ketone ..................................... 28 Fucidin ............................................................... 65 Fusidic acid.................................................. 51, 65 G Gabapentin .................................................. 63, 67 Generaid Plus..................................................... 62 Gentamicin sulphate ........................................... 31 Ginet 84 ............................................................. 30 Gold Knight ........................................................ 66 Gold Pepti Junior................................................ 59 Goldshield.......................................................... 59 Gopten ............................................................... 47 H Haloperidol ........................................................ 50 High calorie products ......................................... 27 High fat low carbohydrate formula ...................... 23 High protein products ......................................... 43 Homatropine hydrobromide ................................ 66 Home Essential ............................................ 54, 62 Humalog Mix 25................................................. 51 Humalog Mix 50................................................. 51 Humira............................................................... 40 HumiraPen ......................................................... 40 Hydralazine hydrochloride .................................. 23 Hydrocortisone ............................................ 25, 49 Hylo-Fresh ......................................................... 22 Hyoscine (scopolamine)..................................... 39 Hypromellose with dextran ........................... 27, 50 I Influenza vaccine................................................ 60 Insulin lispro with insulin lispro protamine ........... 51

70


Index

Pharmaceuticals and brands Insulin pump infusion set (steel cannula) ............ 24 Insulin pump infusion set (teflon cannula, angle insertion) ............................................... 24 Insulin pump infusion set (teflon cannula, angle insertion with insertion device) ............... 24 Insulin pump infusion set (teflon cannula, straight insertion) ............................................ 24 Insulin pump infusion set (teflon cannula, straight insertion with insertion device) ............ 24 Insulin pump reservoir ........................................ 24 Insulin syringes, disposable with attached needle ............................................... 66 Intelence ............................................................ 62 Interferon alpha-2a ............................................. 67 Indapamide ........................................................ 49 Interferon beta-1-alpha ....................................... 50 Ipratropium bromide ........................................... 53 Isoniazid ............................................................ 48 Isopto carpine .................................................... 46 Isopto homatropine ............................................ 66 Ispaghula (psyllium) husk................................... 30 Ispaguhula (phyllium) husk................................. 51 Itraconazole ................................................. 48, 49 Itrazole ......................................................... 48, 49 K Karicare food thickener....................................... 59 KetoCal 4:1 ........................................................ 23 Ketone blood beta-ketone electrodes ............ 28, 61 Konsyl-D...................................................... 30, 51 L Lamivudine .................................................. 33, 45 Leuprorelin......................................................... 67 Levodopa with carbidopa ................................... 62 Levonorgestrel ....................................... 51, 54, 65 Levothyroxine .................................................... 59 Lidocaine-Claris ............................... 21, 23, 39, 48 Lidocaine [lignocaine] hydrochloride .................... 21, 23, 39, 48, 52, 61 Lignocaine hydrochloride ................................... 48 Lincocin ............................................................. 67 Lincomycin ........................................................ 67 Liquigen ....................................................... 22, 65 Lovir .................................................................. 52 Lucrin Depot ...................................................... 67 M Macrogol 400 and propylene glycol .................... 20 Macrogol 3350 .................................................. 22 Malathion with permethrin and piperonyl butoxide ..................................... 23, 54 Marevan............................................................. 49 Medroxyprogesterone acetate............................. 51 Mercury Pharma ................................................ 59 Methylcellulose ............................................ 54, 66 Metolazone .................................................. 23, 45 Magnesium sulphate .......................................... 66 Mercaptopurine ............................................ 50, 59 Mesna ......................................................... 27, 50 Metamide........................................................... 46 Methotrexate ...................................................... 53 Methylprednisolone sodium succinate ................ 62 Metoclopramide hydrochloride ........................... 46 Metopirone ........................................................ 54 Metyrapone........................................................ 54 Mianserin hydrochloride ..................................... 26 Micolette ............................................................ 51 Miconazole ........................................................ 64 Minocycline hydrochloride.................................. 31 Mino-tabs .......................................................... 31 Mitomycin C ................................................ 27, 50 Morphine sulphate.............................................. 52 Morphine tartrate ................................................ 52 Motetis .............................................................. 52 Movicol.............................................................. 22 Moxifloxacin....................................................... 32 Mucilaginous laxatives ....................................... 30 MultiADE............................................................ 66 Mvite ................................................................. 21 N Naltraccord ............................................ 27, 50, 53 Naltrexone hydrochloride ........................ 27, 50, 53 Neocate ............................................................. 63 Neocate Advance ............................................... 64 Neostigmine metilsulfate .................................... 25 Neulastim .......................................................... 21 Next Choice ................................................. 51, 65 Nifedipine........................................................... 49 Nitrados ............................................................. 53 Nitrazepam......................................................... 53 Nupentin ...................................................... 63, 67 Nutrison Multi Fibre ............................................ 65 Nutrison Standard RTH....................................... 65 Nyefax Retard .................................................... 49 O Oestrogens ........................................................ 67 Olanzapine ......................................................... 26 Olanzapine pamoate monohydrate ...................... 26 OncoTICE........................................................... 53 Oral feed 2 kcal/ml ....................................... 20, 68 Ospamox Paediatric Drops ................................. 67 Oxycodone hydrochloride ................................... 20 Oxydone BNM .................................................... 20 P Pacific Buspirone ............................................... 27 Paediatric products ............................................ 44

71


Index

Pharmaceuticals and brands Paediatric products for children with chronic renal failure......................................... 44 Pamidronate disodium ....................................... 64 Pamisol ............................................................. 64 Pantocid IV ........................................................ 62 Pantoprazole ...................................................... 62 Para Plus ..................................................... 23, 54 Pedialyte – Fruit ................................................. 62 Pedialyte – Plain................................................. 62 Pegfilgrastim ...................................................... 21 Pegasys............................................................. 38 Pegasys RBV Combination Pack ........................ 38 Pegylated interferon alpha-2a ............................. 38 Pepti Junior Gold................................................ 59 Pepti Junior Gold Karicare Aptami....................... 45 Pepti Junior Gold Karicare Aptamil ...................... 59 Perindopril ................................. 23, 25, 46, 49, 54 Pharmacy Health Sorbolene with Glycerin ........... 21 Pharmacy services..................... 22, 23, 62, 63, 66 Phenobarbitone sodium...................................... 22 Phlexy 10........................................................... 66 Pilocarpine ......................................................... 46 PKU Anamix Junior ............................................ 23 PMS-Bosentan ................................................... 23 Poly-Gel ............................................................. 20 Poly-Tears ................................................... 27, 50 Postinor-1.......................................................... 54 Praziquantel ....................................................... 54 Prednisone................................................... 25, 30 Premarin ............................................................ 67 Preservative free ocular lubricants ...................... 22 Promethazine winthrop elixir ............................... 63 Progesterone ..................................................... 20 Promethazine hydrochloride ............................... 63 Propranolol ........................................................ 62 Propylthiouracil .................................................. 30 Protamine sulphate ............................................ 30 Protein ............................................................... 43 PTU ................................................................... 30 Puri-nethol ................................................... 50, 59 Purinethol .......................................................... 59 Q Quetiapine.................................................... 20, 67 Quinapril ...................................................... 30, 62 R Raloxifene hydrochloride .................................... 25 Renal oral feed 1kcal/ml ..................................... 44 Renal oral feed 2 kcal/ml .................................... 22 Renal oral feed 2kcal/ml ..................................... 44 Renal products................................................... 44 Renilon 7.5 ........................................................ 22 Respiratory products .......................................... 43 Retinol palmitate ................................................ 22 Retrovir .............................................................. 50 Rifinah ............................................................... 48 Rivaroxaban ....................................................... 64 Rocaltrol solution ............................................... 67 Roferon-A .......................................................... 67 S Salbutamol......................................................... 62 Scopoderm TTS ................................................. 39 Serenace ........................................................... 50 Sertraline ........................................................... 52 Sildenafil ............................................................ 64 Sinemet ............................................................. 62 Sinemet CR........................................................ 62 Sodium citrate with sodium lauryl sulphoacetate.................................................. 51 Sodium cromoglycate ........................................ 66 Sodium hyaluronate ........................................... 22 Sodium tetradecyl sulphate ................................ 65 Solian ................................................................ 54 Solifenacin succinate ......................................... 30 Solu-Cortef .................................................. 25, 49 Solu-Medrol ....................................................... 62 Specialised and elemental products .................... 44 Spironolactone ................................................... 51 Spirotone ........................................................... 51 Stavudine [D4t] .................................................. 63 Sumatriptan ........................................... 39, 53, 66 Suplena ............................................................. 44 Systane Unit Dose .............................................. 20 T Taxotere............................................................. 53 Temaccord ........................................................ 53 Temozolomide ................................................... 53 Tenofovir disoproxil fumarate ............................. 34 Terazosin ........................................................... 51 Tetrabenazine..................................................... 52 Ticagrelor .......................................................... 21 Titralac .............................................................. 64 Tolterodine ......................................................... 30 Tolvon ............................................................... 26 Trandolapril ........................................................ 47 Two Cal HN.................................................. 20, 68 Tyloxapol ........................................................... 64 U Univent .............................................................. 53 Uromitexan .................................................. 27, 50 Ursodeoxycholic acid ......................................... 29 Ursosan ............................................................. 29 Utrogestan ......................................................... 20 V Valaciclovir ........................................................ 35

72


Index

Pharmaceuticals and brands Valtrex ............................................................... 35 Vancomycin hydrochloride ................................. 32 Venlafaxine ........................................................ 52 Ventolin ............................................................. 62 Veracol .............................................................. 31 Vesicare............................................................. 30 Viagra ................................................................ 64 Vincristine sulphate ............................................ 53 Viread ................................................................ 34 Vitala-C .............................................................. 66 Vitamin b complex........................................ 21, 66 Vitamins ...................................................... 21, 66 VitA-POS............................................................ 22 Vytorin ............................................................... 51 W Warfarin sodium................................................. 49 Wasp venom allergy treatment ........................... 41 X Xarelto ............................................................... 64 Xylocaine ............................................... 39, 48, 52 Xylocaine Viscous .............................................. 48 Z Zapril ................................................................. 51 Zaroxolyn ..................................................... 23, 45 Zeffix.................................................................. 33 Zerit ................................................................... 63 Zetlam ......................................................... 33, 45 Zidovudine [azt] ................................................. 50 Zinacef ............................................................... 65 Zoledronic acid .................................................. 26 Zyban .......................................................... 20, 62 Zyprexa Relprevv................................................ 26

73


Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand

Metadata

Title

Schedule Update - effective 1 August 2013

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 August 2013 Cumulative for May, June, July and August 2013 Contents Summary of PHARMAC decisions effective 1 August 2013 …. 3 Pharmacist Prescribers – new designated prescribers ….. 6 Risperidone…

Page 1

icon

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.